<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>BioMed Central</PublisherName>
    <PublisherLocation>London</PublisherLocation>
    <PublisherImprintName>BioMed Central</PublisherImprintName>
  </PublisherInfo>
  <Journal OutputMedium="Online">
    <JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered">
      <JournalID>12974</JournalID>
      <JournalElectronicISSN>1742-2094</JournalElectronicISSN>
      <JournalTitle>Journal of Neuroinflammation</JournalTitle>
      <JournalAbbreviatedTitle>J Neuroinflammation</JournalAbbreviatedTitle>
      <JournalSubjectGroup>
        <JournalSubject Code="SCB" Type="Primary">Biomedicine</JournalSubject>
        <JournalSubject Code="SCB18006" Priority="1" Type="Secondary">Neurosciences</JournalSubject>
        <JournalSubject Code="SCH36001" Priority="2" Type="Secondary">Neurology</JournalSubject>
        <JournalSubject Code="SCL25066" Priority="3" Type="Secondary">Neurobiology</JournalSubject>
        <JournalSubject Code="SCB14000" Priority="4" Type="Secondary">Immunology</JournalSubject>
        <SubjectCollection Code="Biomedical and Life Sciences">SC3</SubjectCollection>
      </JournalSubjectGroup>
    </JournalInfo>
    <Volume OutputMedium="Online">
      <VolumeInfo TocLevels="0" VolumeType="Regular">
        <VolumeIDStart>13</VolumeIDStart>
        <VolumeIDEnd>13</VolumeIDEnd>
        <VolumeIssueCount>1</VolumeIssueCount>
      </VolumeInfo>
      <Issue IssueType="Regular" OutputMedium="Online">
        <IssueInfo IssueType="Regular" TocLevels="0">
          <IssueIDStart>1</IssueIDStart>
          <IssueIDEnd>1</IssueIDEnd>
          <IssueArticleCount>0</IssueArticleCount>
          <IssueHistory>
            <CoverDate>
              <Year>2016</Year>
              <Month>12</Month>
            </CoverDate>
            <PricelistYear>2016</PricelistYear>
          </IssueHistory>
          <IssueCopyright>
            <CopyrightHolderName>The Author(s)</CopyrightHolderName>
            <CopyrightYear>2016</CopyrightYear>
          </IssueCopyright>
        </IssueInfo>
        <Article ID="s12974-016-0598-3" OutputMedium="Online">
          <ArticleInfo ArticleType="OriginalPaper" ContainsESM="Yes" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
            <ArticleID>598</ArticleID>
            <ArticleDOI>10.1186/s12974-016-0598-3</ArticleDOI>
            <ArticleCitationID>145</ArticleCitationID>
            <ArticleSequenceNumber>145</ArticleSequenceNumber>
            <ArticleTitle Language="En" OutputMedium="All">Neuronal seipin knockout facilitates Aβ-induced neuroinflammation and neurotoxicity via reduction of PPARγ in hippocampus of mouse</ArticleTitle>
            <ArticleCategory>Research</ArticleCategory>
            <ArticleFirstPage>1</ArticleFirstPage>
            <ArticleLastPage>14</ArticleLastPage>
            <ArticleHistory>
              <RegistrationDate>
                <Year>2016</Year>
                <Month>5</Month>
                <Day>24</Day>
              </RegistrationDate>
              <Received>
                <Year>2016</Year>
                <Month>1</Month>
                <Day>27</Day>
              </Received>
              <Accepted>
                <Year>2016</Year>
                <Month>5</Month>
                <Day>24</Day>
              </Accepted>
              <OnlineDate>
                <Year>2016</Year>
                <Month>6</Month>
                <Day>10</Day>
              </OnlineDate>
            </ArticleHistory>
            <ArticleFundingInformation>
              <Fund>
                <FunderName>National 973 Basic Research Program of China</FunderName>
                <GrantNumber GrantRecipient="Au8" Type="FundRef">2014CB943303</GrantNumber>
              </Fund>
              <Fund>
                <FunderName FundRefID="http://dx.doi.org/10.13039/501100001809">National Natural Science Foundation of China</FunderName>
                <GrantNumber GrantRecipient="Au8" Type="FundRef">31171440, 81361120247, and 81471157</GrantNumber>
              </Fund>
            </ArticleFundingInformation>
            <ArticleCopyright>
              <CopyrightHolderName>The Author(s).</CopyrightHolderName>
              <CopyrightYear>2016</CopyrightYear>
              <License SubType="CC BY + CC0" Type="OpenAccess" Version="4.0">
                <SimplePara>
                           <Emphasis Type="Bold">Open Access</Emphasis>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ExternalRef>
                    <RefSource>http://creativecommons.org/licenses/by/4.0/</RefSource>
                    <RefTarget Address="http://creativecommons.org/licenses/by/4.0/" TargetType="URL"/>
                  </ExternalRef>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ExternalRef>
                    <RefSource>http://creativecommons.org/publicdomain/zero/1.0/</RefSource>
                    <RefTarget Address="http://creativecommons.org/publicdomain/zero/1.0/" TargetType="URL"/>
                  </ExternalRef>) applies to the data made available in this article, unless otherwise stated.</SimplePara>
              </License>
            </ArticleCopyright>
            <ArticleGrants Type="OpenChoice">
              <MetadataGrant Grant="OpenAccess"/>
              <AbstractGrant Grant="OpenAccess"/>
              <BodyPDFGrant Grant="OpenAccess"/>
              <BodyHTMLGrant Grant="OpenAccess"/>
              <BibliographyGrant Grant="OpenAccess"/>
              <ESMGrant Grant="OpenAccess"/>
            </ArticleGrants>
          </ArticleInfo>
          <ArticleHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1 Aff3" EqualContribution="Yes" ID="Au1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Yun</GivenName>
                  <FamilyName>Qian</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff2" EqualContribution="Yes" ID="Au2">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Jun</GivenName>
                  <FamilyName>Yin</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1 Aff2" ID="Au3">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Juan</GivenName>
                  <FamilyName>Hong</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1 Aff2" ID="Au4">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Guoxi</GivenName>
                  <FamilyName>Li</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff2" ID="Au5">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Baofeng</GivenName>
                  <FamilyName>Zhang</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff4" ID="Au6">
                <AuthorName DisplayOrder="Western">
                  <GivenName>George</GivenName>
                  <FamilyName>Liu</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff3" CorrespondingAffiliationID="Aff3" ID="Au7">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Qi</GivenName>
                  <FamilyName>Wan</FamilyName>
                </AuthorName>
                <Contact>
                  <Phone>+86-25-83714511</Phone>
                  <Fax>+86-25-86260332</Fax>
                  <Email>qi_wan@126.com</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff1 Aff2" CorrespondingAffiliationID="Aff2" ID="Au8">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Ling</GivenName>
                  <FamilyName>Chen</FamilyName>
                </AuthorName>
                <Contact>
                  <Phone>+86-25-86862878</Phone>
                  <Fax>+86-25-86862878</Fax>
                  <Email>lingchen@njmu.edu.cn</Email>
                </Contact>
              </Author>
              <Affiliation ID="Aff1">
                <OrgName>State Key Laboratory of Reproductive Medicine</OrgName>
                <OrgAddress>
                  <Street>Hanzhong Road 140</Street>
                  <City>Nanjing</City>
                  <Postcode>210029</Postcode>
                  <Country Code="CN">China</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff2">
                <OrgDivision>Department of Physiology</OrgDivision>
                <OrgName>Nanjing Medical University</OrgName>
                <OrgAddress>
                  <Street>Hanzhong Road 140</Street>
                  <City>Nanjing</City>
                  <Postcode>210029</Postcode>
                  <Country Code="CN">China</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff3">
                <OrgDivision>Department of Neurology</OrgDivision>
                <OrgName>First Affiliated Hospital of Nanjing Medical University</OrgName>
                <OrgAddress>
                  <Street>Guangzhou Road 300</Street>
                  <City>Nanjing</City>
                  <Postcode>210029</Postcode>
                  <Country Code="CN">China</Country>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff4">
                <OrgDivision>Institute of Cardiovascular Sciences</OrgDivision>
                <OrgName>Peking University and Key Laboratory of Cardiovascular Sciences, China Administration of Education</OrgName>
                <OrgAddress>
                  <City>Beijing</City>
                  <Postcode>100191</Postcode>
                  <Country Code="CN">China</Country>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1" Language="En" OutputMedium="All">
              <Heading>Abstract</Heading>
              <AbstractSection ID="ASec1">
                <Heading>Background</Heading>
                <Para ID="Par1">A characteristic phenotype of congenital generalized lipodystrophy 2 (CGL2) that is caused by loss-of-function of seipin gene is mental retardation. Seipin is highly expressed in hippocampal pyramidal cells and astrocytes. Neuronal knockout of seipin in mice (<Emphasis Type="Italic">seipin</Emphasis>-KO mice) reduces the hippocampal peroxisome proliferator-activated receptor gamma (PPARγ) level without the loss of pyramidal cells. The down-regulation of PPARγ has gained increasing attention in neuroinflammation of Alzheimer’s disease (AD). Thus, the present study focused on exploring the influence of seipin depletion on β-amyloid (Aβ)-induced neuroinflammation and Aβ neurotoxicity.</Para>
              </AbstractSection>
              <AbstractSection ID="ASec2">
                <Heading>Methods</Heading>
                <Para ID="Par2">Adult male <Emphasis Type="Italic">seipin</Emphasis>-KO mice were treated with a single intracerebroventricular (i.c.v.) injection of Aβ<Subscript>25–35</Subscript> (1.2 nmol/mouse) or Aβ<Subscript>1–42</Subscript> (0.1 nmol/mouse), generally a non-neurotoxic dose in wild-type (WT) mice. Spatial cognitive behaviors were assessed by Morris water maze and Y-maze tests, and hippocampal CA1 pyramidal cells and inflammatory responses were examined.</Para>
              </AbstractSection>
              <AbstractSection ID="ASec3">
                <Heading>Results</Heading>
                <Para ID="Par3">The Aβ<Subscript>25–35/1–42</Subscript> injection in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice caused approximately 30–35 % death of pyramidal cells and production of Hoechst-positive cells with the impairment of spatial memory. In comparison with the WT mice, the number of astrocytes and microglia in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice had no significant difference, whereas the levels of IL-6 and TNF-α were slightly increased. Similarly, the Aβ<Subscript>25–35/1–42</Subscript> injection in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice rather than the WT mice could stimulate the activation of astrocytes or microglia and further elevated the levels of IL-6 and TNF-α. Treatment of the <Emphasis Type="Italic">seipin</Emphasis>-KO mice with the PPARγ agonist rosiglitazone (rosi) could prevent Aβ<Subscript>25–35/1–42</Subscript>-induced neuroinflammation and neurotoxicity, which was blocked by the PPARγ antagonist GW9962. In the <Emphasis Type="Italic">seipin</Emphasis>-KO mice, the level of glycogen synthase kinase-3β (GSK3β) phosphorylation at Tyr216 was elevated, while at Ser9, it was reduced compared to the WT mice, which were corrected by the rosi treatment but were unaffected by the Aβ<Subscript>25–35</Subscript> injection.</Para>
              </AbstractSection>
              <AbstractSection ID="ASec4">
                <Heading>Conclusions</Heading>
                <Para ID="Par4">Seipin deficiency in astrocytes increases GSK3β activity and levels of IL-6 and TNF-α through reducing PPARγ, which can facilitate Aβ<Subscript>25–35/1–42</Subscript>-induced neuroinflammation to cause the death of neuronal cells and cognitive deficits.</Para>
              </AbstractSection>
            </Abstract>
            <KeywordGroup Language="En" OutputMedium="All">
              <Heading>Keywords</Heading>
              <Keyword>Seipin</Keyword>
              <Keyword>β-amyloid (Aβ)</Keyword>
              <Keyword>Neuroinflammation</Keyword>
              <Keyword>Peroxisome proliferator-activated receptor gamma (PPARγ)</Keyword>
              <Keyword>Glycogen synthase kinase-3 (GSK3)</Keyword>
            </KeywordGroup>
            <ArticleNote Type="ESMHint">
              <Heading>Electronic supplementary material</Heading>
              <SimplePara>The online version of this article (doi:<ExternalRef>
                  <RefSource>10.1186/s12974-016-0598-3</RefSource>
                  <RefTarget Address="10.1186/s12974-016-0598-3" TargetType="DOI"/>
                </ExternalRef>) contains supplementary material, which is available to authorized users.</SimplePara>
            </ArticleNote>
          </ArticleHeader>
          <Body>
            <Section1 ID="Sec1">
              <Heading>Background</Heading>
              <Para ID="Par5">Congenital generalized lipodystrophy (CGL) is an autosomal recessive disorder that is characterized by a near-total loss of adipose tissue [<CitationRef CitationID="CR1">1</CitationRef>]. Genome-wide linkage analysis has identified two loci related to CGL, i.e., CGL1 mutations in the 1-acylglycerol-3-phosphate O-acyl transferase 2 (AGPAT2) gene and CGL2 mutations in the Berardinelli-Seip congenital lipodystrophy 2 (BSCL2) gene that encodes seipin [<CitationRef CitationID="CR2">2</CitationRef>]. CGL2 patients with loss-of-function mutations in the seipin gene exhibit much higher rates of mental retardation than CGL1 patients [<CitationRef CitationID="CR3">3</CitationRef>, <CitationRef CitationID="CR4">4</CitationRef>]. Seipin is highly expressed in the neuronal cells of the cortex, cerebellum, hippocampus, and hypothalamus [<CitationRef CitationID="CR5">5</CitationRef>, <CitationRef CitationID="CR6">6</CitationRef>]. The seipin knockout in rats or mice causes spatial cognitive deficits through the synaptic dysfunction in hippocampal CA1 regions without loss of pyramidal cells [<CitationRef CitationID="CR5">5</CitationRef>, <CitationRef CitationID="CR7">7</CitationRef>].</Para>
              <Para ID="Par6">Seipin, an exclusive endoplasmic reticulum-residing N-glycosylated protein, can affect the generation of peroxisome proliferator-activated receptor gamma (PPARγ) [<CitationRef CitationID="CR8">8</CitationRef>]. The level of PPARγ is reduced in the embryonic fibroblasts of seipin-deficient mice [<CitationRef CitationID="CR9">9</CitationRef>]. We have recently reported that the neuronal knockout of seipin in mice (<Emphasis Type="Italic">seipin</Emphasis>-KO mice) reduces the expression of the hippocampal PPARγ [<CitationRef CitationID="CR7">7</CitationRef>, <CitationRef CitationID="CR10">10</CitationRef>, <CitationRef CitationID="CR11">11</CitationRef>]. The PPARγ is expressed in astrocytes and microglia and exerts an anti-inflammatory effect [<CitationRef CitationID="CR12">12</CitationRef>]. PPARγ agonists can inhibit the activations of microglia and astrocytes [<CitationRef CitationID="CR13">13</CitationRef>] and reduce the production of pro-inflammatory cytokines [<CitationRef CitationID="CR14">14</CitationRef>]. PPARγ deficiency has been reported to increase the neuroinflammation in allergic encephalomyelitis [<CitationRef CitationID="CR15">15</CitationRef>] and multiple sclerosis [<CitationRef CitationID="CR16">16</CitationRef>]. The levels of pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), are elevated in Alzheimer’s disease (AD) brains [<CitationRef CitationID="CR17">17</CitationRef>]. The activation of PPARγ can enhance the cognitive reserve in humans with AD and in mouse model for AD amyloidosis [<CitationRef CitationID="CR18">18</CitationRef>]. The activation of PPARγ can improve hippocampus-dependent cognitive deficits in AD mouse models [<CitationRef CitationID="CR19">19</CitationRef>]. The PPARγ activation has been recently shown to mitigate the neuronal inflammation in chronic and acute neurological insults [<CitationRef CitationID="CR20">20</CitationRef>]. The PPARγ has received increasing attention in AD due to its anti-inflammatory function [<CitationRef CitationID="CR21">21</CitationRef>]. The hippocampal astrocytes express the seipin protein [<CitationRef CitationID="CR10">10</CitationRef>]. Thus, it should be interesting to examine whether seipin deficiency in astrocytes through reducing PPARγ affects Aβ-induced neuroinflammation and neurotoxicity.</Para>
              <Para ID="Par7">The beneficial effects of PPARγ ligands potentially involve the suppression of signal transducer and activator of transcription (STAT) [<CitationRef CitationID="CR22">22</CitationRef>]. Li et al. have reported the elevation of STAT3 activity in the hippocampus of <Emphasis Type="Italic">seipin-</Emphasis>KO mice [<CitationRef CitationID="CR10">10</CitationRef>]. The STAT family of transcription factors has a central role in inflammatory reactions through regulating the expressions of multiple cytokines. In addition, the activation of STAT3 is known to be crucial for the differentiation of astrocytes [<CitationRef CitationID="CR23">23</CitationRef>]. Adult <Emphasis Type="Italic">seipin-</Emphasis>KO mice showed an increase in the astrocytic differentiation of progenitor cells in the hippocampal dentate gyrus, which can be corrected by the activation of PPARγ [<CitationRef CitationID="CR10">10</CitationRef>]. The STAT3 activation is highly dependent on the phosphorylation of glycogen synthase kinase-3 (GSK3) [<CitationRef CitationID="CR24">24</CitationRef>]. GSK3 is a constitutively active Ser/Thr kinase consisting of GSK3α and GSK3β isoforms. GSK3β has been identified as a strong promoter of pro-inflammatory cytokines, including TNF-α and IL-6 [<CitationRef CitationID="CR25">25</CitationRef>, <CitationRef CitationID="CR26">26</CitationRef>].</Para>
              <Para ID="Par8">Among the Aβ fragments, a peptide bearing 11 amino acids (25–35) (Aβ<Subscript>25–35</Subscript>) is the shortest fragment of Aβ that is processed in vivo by brain proteases [<CitationRef CitationID="CR27">27</CitationRef>]. This peptide retains the ability to self-aggregate and elicits essentially the same toxicity as the full-length peptide despite lacking the hydrophobic C terminal sequence of five amino acids that is present in Aβ<Subscript>1–40</Subscript> [<CitationRef CitationID="CR28">28</CitationRef>]. In this study, we treated the adult male <Emphasis Type="Italic">seipin</Emphasis>-KO mice with a single i.c.v. injection of Aβ<Subscript>25–35</Subscript> at a non-neurotoxic dose in control mice [<CitationRef CitationID="CR29">29</CitationRef>, <CitationRef CitationID="CR30">30</CitationRef>], and then observed the Aβ<Subscript>25–35</Subscript> neurotoxicity (the death of the hippocampal pyramidal cells) and Aβ<Subscript>25–35</Subscript>-induced neuroinflammation (the activation of astrocytes and microglia, the levels of IL-6 and TNF-α). To test the involvement of reduced PPARγ by seipin deficiency, we investigated the effects of the PPARγ agonist and the PPARγ antagonist on Aβ<Subscript>25–35</Subscript>-induced neuroinflammation and Aβ<Subscript>25–35</Subscript> neurotoxicity in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice. The results of the present study indicate that seipin deficiency in astrocytes facilitates the Aβ<Subscript>25–35</Subscript>-induced neuroinflammation through reducing PPARγ to elevate GSK3β activity, which causes the death of pyramidal cells leading to the spatial cognitive deficits.</Para>
            </Section1>
            <Section1 ID="Sec2">
              <Heading>Methods</Heading>
              <Section2 ID="Sec3">
                <Heading>Generation of seipin knockout (<Emphasis Type="Italic">seipin</Emphasis>-KO) mice</Heading>
                <Para ID="Par9">All animal handling procedures followed the guidelines for Laboratory Animal Research of Nanjing Medical University. The use of animals was approved by the Institutional Animal Care and Use Committee of Nanjing Medical University. The mice were maintained in constant environmental conditions (temperature 23 ± 2 °C, humidity 55 ± 5 %, and a 12:12-h light/dark cycle). The neuronal <Emphasis Type="Italic">seipin</Emphasis>-KO mice were generated as described elsewhere [<CitationRef CitationID="CR11">11</CitationRef>]. The genotypes of the <Emphasis Type="Italic">seipin</Emphasis>-KO mice were identified by PCR using genomic DNA from their tails. The DNA was amplified with the following primers: 5′-CTTGTCTCAAAGGGGTCT-3′ (forward primer for loxP) and 5′-TCAACAGAACAGACGCT-3′ (reverse primer for loxP); and 5′-GCGGTCTGGCAGTAAAAACTATC-3′ (forward primer for nestin-Cre) and 5′-GTGAAACAGCATTGCTGTCACTT-3′ (reverse primer for nestin-Cre). All animals received a standard laboratory diet before and after all procedures. In this study, 16-week-old male <Emphasis Type="Italic">seipin</Emphasis>-KO mice (<Emphasis Type="Italic">n</Emphasis> = 88) and wild-type (WT) mice (<Emphasis Type="Italic">n</Emphasis> = 56) were used at the beginning of all experiments. All mice were randomly assigned to one of the following six experimental groups: WT mice (<Emphasis Type="Italic">n</Emphasis> = 24), Aβ<Subscript>25–35</Subscript>-treated WT mice (Aβ<Subscript>25–35</Subscript>-mice, <Emphasis Type="Italic">n</Emphasis> = 16), Aβ<Subscript>1–42</Subscript>-treated WT mice (Aβ<Subscript>1–42</Subscript>-mice, <Emphasis Type="Italic">n</Emphasis> = 16), <Emphasis Type="Italic">seipin</Emphasis>-KO mice (<Emphasis Type="Italic">n</Emphasis> = 32), Aβ<Subscript>25–35</Subscript>-treated <Emphasis Type="Italic">seipin</Emphasis>-KO mice (Aβ<Subscript>25–35</Subscript>-KO mice, <Emphasis Type="Italic">n</Emphasis> = 40), and Aβ<Subscript>1–42</Subscript>-treated <Emphasis Type="Italic">seipin</Emphasis>-KO mice (Aβ<Subscript>1–42</Subscript>-KO mice, <Emphasis Type="Italic">n</Emphasis> = 16). Each experiment was performed by two experimenters who were blinded to the experimental groups. The behavioral tests (<Emphasis Type="Italic">n</Emphasis> = 16 mice for each group) and histological observations (<Emphasis Type="Italic">n</Emphasis> = 8 mice for each group) or Western blot analyses (<Emphasis Type="Italic">n</Emphasis> = 8 mice for each group) were sequentially performed in the same cohorts.</Para>
              </Section2>
              <Section2 ID="Sec4">
                <Heading>Injection (i.c.v.) of Aβ<Subscript>25–35</Subscript> and Aβ<Subscript>1–42</Subscript>
                        </Heading>
                <Para ID="Par10">The Aβ<Subscript>25–35</Subscript> (Sigma, St. Louis, MO, USA) was aggregated by incubation in distilled water (1 mg/ml) at 37 °C for 4 days and diluted to the final concentration with saline immediately before the experiment [<CitationRef CitationID="CR30">30</CitationRef>]. After this treatment, two types of birefringent fibril-like structures and globular aggregates of Aβ<Subscript>25–35</Subscript> can be observed by light microscopic observation [<CitationRef CitationID="CR30">30</CitationRef>]. The Aβ<Subscript>1–42</Subscript> (Sigma, St. Louis, MO, USA) was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP, Sigma-Aldrich) and then flash-freezed in liquid nitrogen and lyophilized to completely remove the solvent [<CitationRef CitationID="CR31">31</CitationRef>]. Lyophilized Aβ<Subscript>1–42</Subscript> was dissolved in 100 mM NaOH at a concentration of 6 mg/ml, aliquoted in 50 μl volumes [<CitationRef CitationID="CR32">32</CitationRef>]. The mice were anesthetized with ketamine (100 mg/kg, i.p.) and xylazine (10 mg/kg, i.p.) [<CitationRef CitationID="CR33">33</CitationRef>] and placed in a stereotactic apparatus (Motorized Stereotaxic StereoDrive; Neurostar). The “aggregated” Aβ<Subscript>25–35</Subscript> (1.2 nmol/mouse at 2 μl) or the Aβ<Subscript>1–42</Subscript> (0.1 nmol/2 μl in 0.1 M phosphate-buffered saline) was injected into the ventricles (0.3 mm posterior, 1.0 mm lateral, and 2.5 mm ventral to the bregma) using a stepper-motorized micro-syringe at a rate of 0.3 μl/min [<CitationRef CitationID="CR34">34</CitationRef>]. The injection site was confirmed by the injection of Indian ink in the preliminary experiments. The mice infused with the same volume of vehicle served as the control group.</Para>
              </Section2>
              <Section2 ID="Sec5">
                <Heading>Drug administration</Heading>
                <Para ID="Par11">The PPARγ agonist rosiglitazone (rosi; Enzo, Farmingdale, NY) and the PPARγ antagonist GW9962 (Sigma, St. Louis, MO, USA) were dissolved in dimethyl sulfoxide (DMSO) and then diluted in 0.9 % saline to a final concentration of 0.5 % DMSO. The oral administration (p.o.) of rosi was given daily at a dose of 5 mg/kg [<CitationRef CitationID="CR7">7</CitationRef>]. The GW9962 (1 mg/kg/day) was injected intraperitoneally (i.p.) [<CitationRef CitationID="CR35">35</CitationRef>].</Para>
              </Section2>
              <Section2 ID="Sec6">
                <Heading>Behavioral examination</Heading>
                <Para ID="Par12">The behavioral performances on days 5–14 after Aβ<Subscript>25–35</Subscript> injection were captured via video recording (Winfast PVR; Leadtek Research, Fremont, CA) and analyzed using TopScan Lite 2.0 (Clever Sys., Reston, VA). <Emphasis Type="Italic">Morris water maze task</Emphasis>: The water maze task was consecutively performed to examine the spatial memory [<CitationRef CitationID="CR29">29</CitationRef>]. A pool (diameter = 120 cm) made of black-colored plastic was prepared. The water temperature was maintained at 20 ± 1 °C with a bath heater that was used before the sessions. On days 1–2 of training, a cylindrical black-colored platform (diameter = 7 cm) was placed 0.5 cm above the surface of the water. A mouse was randomly released into one of the four different quadrants and allowed to swim for 90 s. The latency to reach the visible platform was measured. On days 3–7 of the training, the platform was moved to the opposite quadrant of the previously visible platform and submerged 1 cm below the surface of the water. Four trials were conducted each day with an intertrial interval of 30 min. The average swimming speeds (m/s) and latencies (s) to reach the platform were scored for all trials. If the mouse was unable to reach the platform within 90 s, the experimenters gently assisted it onto the platform and allowed it to remain there for 15 s. Each mouse began in one of the four quadrants, which was selected in a random manner. On day 8 of the training, a probe trial was performed by removing the platform. The mouse was released from the opposite quadrant relative to the previous location of the platform and allowed to swim for 90 s. The percentages of swimming time spent in the target quadrant, opposite quadrant, and right and left adjacent quadrants were determined. <Emphasis Type="Italic">Y-maze task</Emphasis>: Spatial working memory performance was assessed by recording spontaneous alternation behavior in a Y-maze [<CitationRef CitationID="CR30">30</CitationRef>]. A Y-maze task was performed 48 h after the probe trial task. The Y-maze was constructed of black-painted wood. Each arm was 40-cm long, 13-cm high, 3-cm wide at the bottom, and 10-cm wide at the top, and the arms converged at equal angles. Each mouse was placed at the end of one arm and allowed to move freely through the maze during an 8-min session. The series of arm entries were recorded visually, and arm entries were considered to be completed when the hind paws of the mouse were completely placed in the arm. Alternations were defined as successive entries into the three arms on overlapping triplet sets. The percentage of alternations was calculated as the ratio of actual to possible alternations (defined as the total number of arm entries minus two). The scorers were blinded to the treatment groups.</Para>
              </Section2>
              <Section2 ID="Sec7">
                <Heading>Histological examination</Heading>
                <Para ID="Par13">The mice were anesthetized with chloral hydrate (400 mg/kg, i.p.) and perfused with 4 % paraformaldehyde. The brains were removed and immersed in 4 % paraformaldehyde at 4 °C overnight.</Para>
                <Para ID="Par14">
                           <Emphasis Type="Italic">Toluidine blue staining</Emphasis>: The brains were processed for paraffin embedding, and coronal sections (5 μm) were cut. The pyramidal cells in the hippocampal CA1 region were identified using a conventional light microscope (Olympus DP70, Tokyo, Japan) with a 60× objective. The healthy pyramidal neurons exhibited round cell bodies with plainly stained nuclei. <Emphasis Type="Italic">Stereological counting CA1 pyramidal cells</Emphasis>: The brains were transferred into 30 % sucrose. After gradient dehydration, the coronal sections of the hippocampus (40 μm) were cut with a freezing microtome (Leica, Nussloch, Germany) and stained with toluidine blue. Every fourth section was obtained for consecutive cell quantification analyses. Stereological cell counting was performed by a stereological system, consisting of a light microscope with a CCD camera (Olympus DP70), a motorized specimen stage for automatic sampling (MicroBrightField, Williston, USA), and a computer running Microbrightfield Stereo Investigator software (Microbrightfield, Williston, VT, USA) [<CitationRef CitationID="CR36">36</CitationRef>]. All counts were performed by the same investigator, who was blind to the treatment. The total numbers of healthy pyramidal cells throughout the hippocampal CA1 region were counted using the optical fractionators’ method. The section thickness was measured using a dissector height of 10 μm. The layer of pyramidal cells was defined according to the terminology of Blackstad [<CitationRef CitationID="CR37">37</CitationRef>]. The boundary between the CA3 and CA1 subregions was identified by the differential thickness of the cell layers and by the smaller cell somas of the CA1 subregion. The boundary between CA1 and the subiculum was defined as the line separating the contiguous cells of CA1 from the more widely spaced cells of the subiculum.</Para>
                <Para ID="Par15">
                           <Emphasis Type="Italic">Hoechst staining</Emphasis>: Coronal paraffin sections (5 μm) were incubated in Hoechst 33342 (1 μg/ml, Cell Signaling Technology, Inc., Boston, MA, USA) for 2 min. <Emphasis Type="Italic">Quantitative analyses of Hoechst-positive cells</Emphasis>: Hoechst-positive (Hoechst<Superscript>+</Superscript>) cells in hippocampal CA1 region were observed by a conventional light microscope (Olympus DP70, Japan) with 60× objective and counted. The density of Hoechst<Superscript>+</Superscript> cells was expressed as the number of cells per millimeter length along the pyramidal cells layer.</Para>
                <Para ID="Par16">
                           <Emphasis Type="Italic">GFAP and Iba1 staining</Emphasis>: The hippocampal sections (40 μm) were cut using a cryostat. Every fourth section was obtained with a randomly chosen starting section. The free-floating sections were blocked with 3 % normal goat serum for 60 min. Glial fibrillary acidic protein (GFAP) and ionized calcium-binding adapter molecule 1 (Iba1) immuno-staining were performed using the following primary antibodies and incubation at 4 °C overnight: mouse anti-GFAP antibody (1:500; Millipore, Billerican, MA, USA) and goat polyclonal anti-Iba1 antibody (1:500; Abcam, Cambridge, UK). Then, the sections were incubated in biotin-labeled goat anti-mouse IgG antibody (1:400; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or biotin-labeled rabbit anti-goat IgG antibody (1:500; Bioworld Technology, Inc., St. Louis Park, MN, USA) for 2 h at room temperature. Immuno-reactivity was visualized based on the avidin-biotin-horseradish peroxidase complex (ABC Elite; Vector Laboratories, Inc., Burlingame, CA, USA).</Para>
                <Para ID="Par17">
                           <Emphasis Type="Italic">Counting GFAP- and Iba1-positive cells in the hippocampal CA1</Emphasis>: The GFAP-positive (GFAP<Superscript>+</Superscript>) cells and Iba1-positive (Iba1<Superscript>+</Superscript>) cells in the hippocampal CA1 radiatum layer were counted using a conventional light microscope (Olympus DP70). The radiatum layer was outlined at ×5 magnification. Systematic random sampling was achieved with a uniform sampling grid superimposed randomly over the region. A counting frame was placed in each square of the grid, and the cells were counted within that frame at ×40 magnification. A cell was counted if the nucleus was stained and was (a) in focus, (b) within the counting frame or crossed the green counting frame inclusion line, and (c) within the optical disector. Total estimated cell number per section = number of counted cells × (1/ssf) × (1/asf) × (1/hsf), where ssf is the section sampling fraction, asf is the area sampling fraction, and hsf is the height sampling fraction [<CitationRef CitationID="CR38">38</CitationRef>]. The densities of GFAP<Superscript>+</Superscript> cells and Iba1<Superscript>+</Superscript> cells are expressed as the mean numbers per mm<Superscript>3</Superscript>, which were normalized to the control value obtained from WT mice [<CitationRef CitationID="CR39">39</CitationRef>].</Para>
                <Para ID="Par18">
                           <Emphasis Type="Italic">Seipin/GFAP or Iba1 double immuno-staining</Emphasis>: The coronal sections (5 μm in thickness) were placed in gelatine-coated slides, blocked with 3 % normal goat serum, and then incubated in rabbit anti-seipin antibody (1:200; Abcam) at 4 °C overnight, which was revealed using CY3-labeled anti-rabbit IgG antibody (1:200; Millipore) or FITC-labeled anti-rabbit antibody (1:200; Millipore) and mouse monoclonal anti-GFAP antibody (1:200; Millipore) or goat polyclonal anti-Iba1 antibody (1:500; Abcam), which was revealed using FITC-labeled anti-mouse antibody (1:50; Millipore) or CY3-labeled anti-goat IgG antibody (1:200; Millipore). The immune-positive cells/fibers were observed by a confocal laser-scanning microscope (Leica, Heidelberg, Germany).</Para>
              </Section2>
              <Section2 ID="Sec8">
                <Heading>Western blot analyses</Heading>
                <Para ID="Par19">The mice were decapitated under deep anesthesia with chloral hydrate. The hippocampus was quickly removed and homogenized in a lysis buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 10 mM NaF, 1 mM sodium orthovanadate, 1 % Triton X-100, 0.5 % sodium deoxycholate, 1 mM phenyl-methylsulfonyl fluoride, and a protease inhibitor cocktail (Complete; Roche, Mannheim, Germany). The protein concentration was determined with a BCA Protein Assay Kit (Pierce Biotechnology, Rockford, IL, USA). The total proteins (20 μg) were separated by SDS-poly-acrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene difluoride membrane. The membranes were incubated with 5 % nonfat dried milk in Tris-buffered saline containing 0.1 % Tween 20 for 60 min at room temperature and were then incubated with a mouse monoclonal anti-phospho-GSK3β (Tyr216) antibody (1:1000; Cell Signaling Technology), a rabbit monoclonal anti-phospho-GSK3β (Ser9) antibody, and an anti-phospho-STAT3 antibody (1:1000; Cell Signaling Technology); a rabbit polyclonal anti-IL-6 antibody (1:1000; Abcam), a mouse monoclonal anti-TNF-α antibody and a PPARγ antibody (1:200; Santa Cruz Biotechnology); or a mouse monoclonal anti-β-actin antibody (1:1000; Cell Signaling Technology) and a rabbit monoclonal anti-GAPDH antibody (1:1000; Cell Signaling Technology) at 4 °C overnight. The membranes were then incubated with HRP-labeled secondary antibodies (1:10,000; Millipore). The blots were stripped by incubation in a stripping buffer (Restore, Pierce) for 5 min, incubated with rabbit polyclonal antibodies for GSK3β or STAT3 (1:1000; Cell Signaling Technology) and developed using an ECL Detection Kit (Millipore). The Western blot bands were scanned and analyzed with an image analysis software package (ImageJ; NIH Image, Bethesda, MD, USA).</Para>
              </Section2>
              <Section2 ID="Sec9">
                <Heading>Data analysis/statistics</Heading>
                <Para ID="Par20">The data were retrieved and processed with the Microcal Origin 8.0 software. The group data are expressed as the means ± standard errors, and significance was tested with Student’s <Emphasis Type="Italic">t</Emphasis> tests or ANOVAs with or without repeated measures, followed by Bonferroni post hoc analysis for multiple comparisons. The results of the Morris water maze test were analyzed using repeated-measures ANOVA. The statistical analyses were performed using Stata 7 software (STATA Corporation, College Station, TX, USA). Differences were considered statistically significant at <Emphasis Type="Italic">P</Emphasis> &lt; 0.05.</Para>
              </Section2>
            </Section1>
            <Section1 ID="Sec10">
              <Heading>Results</Heading>
              <Section2 ID="Sec11">
                <Heading>Seipin deficiency enhances Aβ<Subscript>25–35</Subscript>-induced cognitive deficits</Heading>
                <Para ID="Par21">Spatial memory was examined using place learning in a Morris water maze task from day 5 after the injection (i.c.v.) of Aβ<Subscript>25–35</Subscript>. The mean latency required to find the visible platform on days 1–2 of training and the subsequent escape latencies to reach the hidden platform on days 3–7 of training are illustrated in Fig. <InternalRef RefID="Fig1">1a</InternalRef>. First, the latency to reach the visible platform was not affected by genotype (<Emphasis Type="Italic">F</Emphasis>
                           <Subscript>(1, 60)</Subscript> = 0.179, <Emphasis Type="Italic">P</Emphasis> = 0.674), Aβ<Subscript>25-35</Subscript> injection (<Emphasis Type="Italic">F</Emphasis>
                           <Subscript>(1, 60)</Subscript> = 0.054, <Emphasis Type="Italic">P</Emphasis> = 0.818), or the genotype × Aβ<Subscript>25–35</Subscript> interaction (<Emphasis Type="Italic">F</Emphasis>
                           <Subscript>(1, 60)</Subscript> = 3.159, <Emphasis Type="Italic">P</Emphasis> = 0.081). Subsequently, repeated-measures ANOVA revealed that the escape latency to reach the hidden platform progressively decreased with training days in all groups (<Emphasis Type="Italic">F</Emphasis>
                           <Subscript>(4, 240)</Subscript> = 71.948, <Emphasis Type="Italic">P</Emphasis> &lt; 0.001), and this effect was influenced by genotype (<Emphasis Type="Italic">F</Emphasis>
                           <Subscript>(1, 60)</Subscript> = 190.133, <Emphasis Type="Italic">P</Emphasis> &lt; 0.001), Aβ<Subscript>25–35</Subscript> (<Emphasis Type="Italic">F</Emphasis>
                           <Subscript>(1, 60)</Subscript> = 39.457, <Emphasis Type="Italic">P</Emphasis> &lt; 0.001), and the genotype × Aβ<Subscript>25–35</Subscript> interaction (<Emphasis Type="Italic">F</Emphasis>
                           <Subscript>(1, 60)</Subscript> = 36.701, <Emphasis Type="Italic">P</Emphasis> &lt; 0.001). The <Emphasis Type="Italic">seipin</Emphasis>-KO mice required longer times to reach the hidden platform on days 5–7 of training than did the WT mice (<Emphasis Type="Italic">P</Emphasis> &lt; 0.01). Furthermore, the Aβ<Subscript>25–35</Subscript>-injected (1.2 nmol/mouse) <Emphasis Type="Italic">seipin</Emphasis>-KO mice exhibited a significantly increased escape latency to the hidden platform (Aβ<Subscript>25–35</Subscript>-KO mice, <Emphasis Type="Italic">P</Emphasis> &lt; 0.01) compared with the <Emphasis Type="Italic">seipin</Emphasis>-KO mice, but this effect was not observed in the Aβ<Subscript>25–35</Subscript>-injected WT mice (Aβ<Subscript>25–35</Subscript>-mice, <Emphasis Type="Italic">P</Emphasis> &gt; 0.05) relative to the non-injected WT mice. However, the mean swimming speeds during the visible platform and hidden platform tests exhibited by Aβ<Subscript>25–35</Subscript>-mice (0.26 ± 0.01 m/s, <Emphasis Type="Italic">P</Emphasis> &gt; 0.05), <Emphasis Type="Italic">seipin</Emphasis>-KO mice (0.27 ± 0.03 m/s, <Emphasis Type="Italic">P</Emphasis> &gt; 0.05), and Aβ<Subscript>25–35</Subscript>-KO mice (0.27 ± 0.04 m/s, <Emphasis Type="Italic">P</Emphasis> &gt; 0.05) were not significantly different from those of the WT mice (0.26 ± 0.03 m/s).<Figure Category="Standard" Float="Yes" ID="Fig1">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 1</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Seipin deficiency enhances Aβ<Subscript>25–35</Subscript>-induced cognitive deficits. <Emphasis Type="Bold">a</Emphasis> The latencies (s) to reach the visible and hidden platforms (<Emphasis Type="Italic">upper panel</Emphasis>) and the swimming speeds (m/s, <Emphasis Type="Italic">bottom panel</Emphasis>) of WT mice (WT), Aβ<Subscript>25–35</Subscript> mice (Aβ), <Emphasis Type="Italic">seipin</Emphasis>-KO mice (KO), and Aβ<Subscript>25–35</Subscript>-KO mice (KO/Aβ) in the Morris water maze (MWM) test. The <Emphasis Type="Italic">left panels</Emphasis> illustrate representative swimming tracks of the mice searching for the underwater platform on day 5 after training. The <Emphasis Type="Italic">black dots</Emphasis> indicate the position of the hidden platform. **<Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. WT mice; <Superscript>##</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. <Emphasis Type="Italic">seipin</Emphasis>-KO mice (repeated-measures ANOVA with Bonferroni’s test). <Emphasis Type="Bold">b</Emphasis> The <Emphasis Type="Italic">bars</Emphasis> represent the percentages of time spent in the target quadrant (TQ), opposite quadrant (OQ), and right (R) and left (L) adjacent quadrants (AQ) of the probe test. The <Emphasis Type="Italic">left panels</Emphasis> illustrate typical tracks. **<Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. WT mice; <Superscript>##</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. <Emphasis Type="Italic">seipin</Emphasis>-KO mice (two-way ANOVA with Bonferroni’s test). <Emphasis Type="Bold">c</Emphasis>, <Emphasis Type="Bold">d</Emphasis> The <Emphasis Type="Italic">bar graphs</Emphasis> display group means in the alternation rate (%) and the numbers of arm entries (8 min) in the Y-maze (Y-M) task. *<Emphasis Type="Italic">P</Emphasis> &lt; 0.05 and **<Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. WT mice; <Superscript>#</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.05 vs. <Emphasis Type="Italic">seipin</Emphasis>-KO mice (two-way ANOVA with Bonferroni’s test)</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO1">
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/12974_2016_598_Fig1_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                        </Para>
                <Para ID="Par22">A probe test was performed 24 h after the hidden platform test to measure the strength of the memory trace. The swimming times spent in the target quadrant, opposite quadrant, and right and left adjacent quadrants are showed in Fig. <InternalRef RefID="Fig1">1b</InternalRef>. The main effect of genotype (<Emphasis Type="Italic">F</Emphasis>
                           <Subscript>(1, 60)</Subscript> = 74.061, <Emphasis Type="Italic">P</Emphasis> &lt; 0.001) and Aβ<Subscript>25–35</Subscript> (<Emphasis Type="Italic">F</Emphasis>
                           <Subscript>(1, 60)</Subscript> = 11.813, <Emphasis Type="Italic">P</Emphasis> = 0.001) were that the <Emphasis Type="Italic">seipin</Emphasis>-KO mice spent less swimming time in the target quadrant than the WT mice (<Emphasis Type="Italic">P</Emphasis> &lt; 0.01). Furthermore, there was a significant interaction of genotype × Aβ<Subscript>25–35</Subscript> (<Emphasis Type="Italic">F</Emphasis>
                           <Subscript>(1, 60)</Subscript> = 13.716, <Emphasis Type="Italic">P</Emphasis> &lt; 0.001). Notably, the swimming time in the target quadrant of the Aβ<Subscript>25–35</Subscript>-KO mice was shorter than that of the <Emphasis Type="Italic">seipin</Emphasis>-KO mice (<Emphasis Type="Italic">P</Emphasis> &lt; 0.01), whereas the Aβ<Subscript>25–35</Subscript>-WT mice exhibited no significant difference compared with the WT mice (<Emphasis Type="Italic">P</Emphasis> &gt; 0.05).</Para>
                <Para ID="Par23">Spatial working memory performance was assessed with a Y-maze task. There was a main effect of genotype on the alternation ratio (<Emphasis Type="Italic">F</Emphasis>
                           <Subscript>(1, 60)</Subscript> = 18.472, <Emphasis Type="Italic">P</Emphasis> &lt; 0.001; Fig. <InternalRef RefID="Fig1">1c</InternalRef>), but no effect on the number of arm entries was observed (<Emphasis Type="Italic">F</Emphasis>
                           <Subscript>(1, 60)</Subscript> = 0.165, <Emphasis Type="Italic">P</Emphasis> = 0.686; Fig. <InternalRef RefID="Fig1">1d</InternalRef>). The alternation ratio of the <Emphasis Type="Italic">seipin</Emphasis>-KO mice was reduced compared to that of the WT mice (<Emphasis Type="Italic">P</Emphasis> &lt; 0.05). Additionally, there was a significant interaction of genotype × Aβ<Subscript>25–35</Subscript> for the alternation ratio (<Emphasis Type="Italic">F</Emphasis>
                           <Subscript>(1, 60)</Subscript> = 7.214, <Emphasis Type="Italic">P</Emphasis> = 0.009). Notably, Aβ<Subscript>25–35</Subscript>-KO mice exhibited a significant reduction in the alternation ratio compared with the <Emphasis Type="Italic">seipin</Emphasis>-KO mice (<Emphasis Type="Italic">P</Emphasis> &lt; 0.05).</Para>
              </Section2>
              <Section2 ID="Sec12">
                <Heading>Activation of PPARγ prevents Aβ<Subscript>25–35</Subscript>-induced cognitive deficits in <Emphasis Type="Italic">seipin</Emphasis>-KO mice</Heading>
                <Para ID="Par24">The level of hippocampal PPARγ exhibited a main effect of genotype (<Emphasis Type="Italic">F</Emphasis>
                           <Subscript>(1, 28)</Subscript> = 12.778, P &lt; 0.001; Fig. <InternalRef RefID="Fig2">2a</InternalRef>) but no effect of Aβ<Subscript>25–35</Subscript> (<Emphasis Type="Italic">F</Emphasis>
                           <Subscript>(1, 28)</Subscript> = 0.037, P = 0.848) or genotype × Aβ<Subscript>25–35</Subscript> interaction (<Emphasis Type="Italic">F</Emphasis>
                           <Subscript>(1, 28)</Subscript> = 0.374, P = 0.546). Compared with the WT mice, the level of hippocampal PPARγ was remarkably reduced in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice (<Emphasis Type="Italic">P</Emphasis> &lt; 0.05) but was not significantly different compared with that in the Aβ<Subscript>25–35</Subscript>-KO mice (<Emphasis Type="Italic">P</Emphasis> &gt; 0.05).<Figure Category="Standard" Float="Yes" ID="Fig2">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 2</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Activation of PPARγ prevents enhanced Aβ<Subscript>25–35</Subscript>-induced cognitive deficits by seipin deficiency. <Emphasis Type="Bold">a</Emphasis> The <Emphasis Type="Italic">bars</Emphasis> indicate the densitometric values of the hippocampal PPARγ protein in WT mice (WT), Aβ<Subscript>25–35</Subscript> mice (Aβ), <Emphasis Type="Italic">seipin</Emphasis>-KO mice (KO), and Aβ<Subscript>25–35</Subscript>-KO mice (KO/Aβ). *<Emphasis Type="Italic">P</Emphasis> &lt; 0.05 vs. WT mice (two-way ANOVA with Bonferroni’s test). <Emphasis Type="Bold">b</Emphasis> Time chart of the experimental procedure. <Emphasis Type="Italic">MWM</Emphasis> Morris water maze task, <Emphasis Type="Italic">Y-M</Emphasis> Y-maze task. <Emphasis Type="Bold">c</Emphasis>
                                       <Emphasis Type="Italic">-i</Emphasis> and <Emphasis Type="Bold">c-</Emphasis>
                                       <Emphasis Type="Italic">ii</Emphasis> Each point represents the group mean latency (s) to reach the visible and hidden platforms in WT mice, vehicle-treated <Emphasis Type="Italic">seipin</Emphasis>-KO mice (KO), rosi-treated <Emphasis Type="Italic">seipin</Emphasis>-KO mice (KO/rosi), Aβ<Subscript>25–35</Subscript>-KO mice (KO/Aβ), and Aβ<Subscript>25–35</Subscript>-KO mice (KO/Aβ/rosi). *<Emphasis Type="Italic">P</Emphasis> &lt; 0.05 and **<Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. WT mice; <Superscript>#</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.05 and <Superscript>##</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. <Emphasis Type="Italic">seipin</Emphasis>-KO mice; <Superscript>++</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. KO/Aβ mice (repeated-measures ANOVA with Bonferroni’s test). <Emphasis Type="Bold">d</Emphasis> The <Emphasis Type="Italic">bars</Emphasis> represent the percentages of time spent in a target quadrant of the probe test. *<Emphasis Type="Italic">P</Emphasis> &lt; 0.05 and **<Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. WT mice; <Superscript>#</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.05 vs. <Emphasis Type="Italic">seipin</Emphasis>-KO mice; <Superscript>++</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. KO/Aβ mice (two-way ANOVA with Bonferroni’s test). <Emphasis Type="Bold">e</Emphasis> 
                                       <Emphasis Type="Italic">Bar graph</Emphasis> indicates the alternation rates (%) in the Y-maze task. *<Emphasis Type="Italic">P</Emphasis> &lt; 0.05 vs. WT mice; <Superscript>#</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.05 vs. <Emphasis Type="Italic">seipin</Emphasis>-KO mice; <Superscript>+</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.05 vs. KO/Aβ mice (two-way ANOVA with Bonferroni’s test)</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO2">
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/12974_2016_598_Fig2_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                        </Para>
                <Para ID="Par25">Consistent with the report by Zhou et al. [<CitationRef CitationID="CR7">7</CitationRef>], the treatment of the <Emphasis Type="Italic">seipin</Emphasis>-KO mice with the PPARγ agonist rosiglitazone (rosi, 5 mg/kg, p.o.) for consecutive 17 days corrected the prolongation of escape latencies to reach the hidden platform (<Emphasis Type="Italic">P</Emphasis> &lt; 0.05, <Emphasis Type="Italic">n</Emphasis> = 16; Fig. <InternalRef RefID="Fig2">2c</InternalRef>-<Emphasis Type="Italic">i</Emphasis>) and the decrease in the swimming time of target quadrant (<Emphasis Type="Italic">P</Emphasis> &lt; 0.05, <Emphasis Type="Italic">n</Emphasis> = 16; Fig. <InternalRef RefID="Fig2">2d</InternalRef>) and the alternation ratio of Y-maze (KO: <Emphasis Type="Italic">P</Emphasis> &lt; 0.05, <Emphasis Type="Italic">n</Emphasis> = 8; Aβ<Subscript>25–35</Subscript>
                           <Emphasis Type="Italic">-</Emphasis>KO: <Emphasis Type="Italic">P</Emphasis> &lt; 0.05, <Emphasis Type="Italic">n</Emphasis> = 8; Fig. <InternalRef RefID="Fig2">2e</InternalRef>). To test the involvement of the reduced PPARγ level in the Aβ<Subscript>25–35</Subscript>-induced cognitive deficits, the rosi treatment was given for consecutive 17 days starting from 2 days before the Aβ<Subscript>25–35</Subscript> injection (Fig. <InternalRef RefID="Fig2">2b</InternalRef>). In comparison with the vehicle-treated Aβ<Subscript>25–35</Subscript>
                           <Emphasis Type="Italic">-</Emphasis>KO mice, the rosi treatment in the Aβ<Subscript>25–35</Subscript>
                           <Emphasis Type="Italic">-</Emphasis>KO mice could perfectly reduce their escape latencies reaching the hidden platform (<Emphasis Type="Italic">P</Emphasis> &lt; 0.01, <Emphasis Type="Italic">n</Emphasis> = 16; Fig. <InternalRef RefID="Fig2">2c</InternalRef>-<Emphasis Type="Italic">ii</Emphasis>) and increase the swimming time in the target quadrant (<Emphasis Type="Italic">P</Emphasis> &lt; 0.01, <Emphasis Type="Italic">n</Emphasis> = 16) and alternation ratio in the Y-maze (<Emphasis Type="Italic">P</Emphasis> &lt; 0.05, <Emphasis Type="Italic">n</Emphasis> = 8).</Para>
              </Section2>
              <Section2 ID="Sec13">
                <Heading>Seipin deficiency enhances Aβ<Subscript>25–35</Subscript>-induced death of neuronal cells via PPARγ reduction</Heading>
                <Para ID="Par26">There was no main effect of genotype (<Emphasis Type="Italic">F</Emphasis>
                           <Subscript>(1, 28)</Subscript> = 1.572, <Emphasis Type="Italic">P</Emphasis> = 0.220; Fig. <InternalRef RefID="Fig3">3a</InternalRef>) or Aβ<Subscript>25–35</Subscript> (<Emphasis Type="Italic">F</Emphasis>
                           <Subscript>(1, 28)</Subscript> = 2.091, <Emphasis Type="Italic">P</Emphasis> = 0.159) on the number of pyramidal cells in the hippocampal CA1 region; however, there was a significant genotype × Aβ<Subscript>25–35</Subscript> interaction (<Emphasis Type="Italic">F</Emphasis>
                           <Subscript>(1, 28)</Subscript> = 4.294, <Emphasis Type="Italic">P</Emphasis> = 0.048). Stereological counts of the surviving pyramidal cells revealed an approximately 35 % loss of pyramidal cells in the Aβ<Subscript>25–35</Subscript>
                           <Emphasis Type="Italic">-</Emphasis>KO mice (<Emphasis Type="Italic">P</Emphasis> &lt; 0.01) and no loss in the Aβ<Subscript>25–35</Subscript>-mice (<Emphasis Type="Italic">P</Emphasis> &gt; 0.05). As illustrated in Fig. <InternalRef RefID="Fig3">3b</InternalRef>, large numbers of Hoechst-positive (Hoechst<Superscript>+</Superscript>) cells were observed in the Aβ<Subscript>25–35</Subscript>-KO mice (<Emphasis Type="Italic">P</Emphasis> &lt; 0.01, <Emphasis Type="Italic">n</Emphasis> = 8) but not in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice (<Emphasis Type="Italic">P</Emphasis> &gt; 0.05, <Emphasis Type="Italic">n</Emphasis> = 8) or the Aβ<Subscript>25–35</Subscript>-mice (<Emphasis Type="Italic">P</Emphasis> &gt; 0.05, <Emphasis Type="Italic">n</Emphasis> = 8). The rosi treatment in the Aβ<Subscript>25–35</Subscript>-KO mice could attenuate the deaths of pyramidal cells (<Emphasis Type="Italic">P</Emphasis> &lt; 0.05) and the number of Hoechst<Superscript>+</Superscript> cells (<Emphasis Type="Italic">P</Emphasis> &lt; 0.01), which were sensitive to the PPARγ antagonist GW9962 (pyramidal cells: <Emphasis Type="Italic">P</Emphasis> &lt; 0.05; Hoechst<Superscript>+</Superscript> cells: <Emphasis Type="Italic">P</Emphasis> &lt; 0.01). The administration of GW9962 alone in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice did not affect the survival of pyramidal cells (<Emphasis Type="Italic">P</Emphasis> &gt; 0.05). Similarly, the Aβ<Subscript>1–42</Subscript> injection in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice rather than the WT mice caused approximately 30 % death of pyramidal cells (<Emphasis Type="Italic">P</Emphasis> &lt; 0.05, <Emphasis Type="Italic">n</Emphasis> = 8; Additional file <InternalRef RefID="MOESM1">1</InternalRef>: Figure S1), which was prevented by the rosi treatment (<Emphasis Type="Italic">P</Emphasis> &lt; 0.05, <Emphasis Type="Italic">n</Emphasis> = 8).<Figure Category="Standard" Float="Yes" ID="Fig3">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 3</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Activation of PPARγ attenuates enhanced Aβ neurotoxicity by seipin deficiency. <Emphasis Type="Bold">a</Emphasis> Representative images of the hippocampal CA1 regions (5-μm sections stained with toluidine blue) in WT mice (WT), Aβ<Subscript>25–35</Subscript> mice (Aβ), <Emphasis Type="Italic">seipin</Emphasis>-KO mice (KO), Aβ<Subscript>25–35</Subscript>-KO mice (KO/Aβ), rosi-treated Aβ<Subscript>25–35</Subscript>-KO mice (KO/Aβ/rosi), GW9662-treated <Emphasis Type="Italic">seipin</Emphasis>-KO mice (KO/GW), and KO/Aβ/rosi mice (KO/Aβ/rosi/GW). <Emphasis Type="Italic">PcL</Emphasis> pyramidal cell layer, <Emphasis Type="Italic">OL</Emphasis> oriens layer. <Emphasis Type="Italic">Scale bars</Emphasis> = 50 μm. The <Emphasis Type="Italic">bar graph</Emphasis> represents the stereological counts of the surviving pyramidal cells. **<Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. WT mice; <Superscript>#</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.05 vs. Aβ<Subscript>25–35</Subscript>-KO mice; <Superscript>+</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.05 vs. KO/Aβ/rosi mice (three-way ANOVA with Bonferroni’s test). <Emphasis Type="Bold">b</Emphasis> Representative images of Hoechst staining in the hippocampal CA1 regions. The <Emphasis Type="Italic">white arrows</Emphasis> indicate the Hoechst<Superscript>+</Superscript> cells. PcL: pyramidal cell layer; RL: radiatum layer. Scale bars = 50 μm. The bars indicate the density of Hoechst<Superscript>+</Superscript> cells. **<Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. WT mice; <Superscript>##</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. Aβ<Subscript>25–35</Subscript>-KO mice; <Superscript>++</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. KO/Aβ/rosi mice (three-way ANOVA with Bonferroni’s test)</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO3">
                      <ImageObject Color="Color" FileRef="MediaObjects/12974_2016_598_Fig3_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                        </Para>
              </Section2>
              <Section2 ID="Sec14">
                <Heading>Seipin deficiency facilitates Aβ<Subscript>25–35</Subscript>-induced inflammation via PPARγ reduction</Heading>
                <Para ID="Par27">Sequentially, we observed that GFAP<Superscript>+</Superscript> astrocytes expressed highly the seipin protein in the hippocampal CA1 region (upper panels in Fig. <InternalRef RefID="Fig4">4a</InternalRef>) but Iba1<Superscript>+</Superscript> microglia did not (bottom panels). The numbers of Iba1<Superscript>+</Superscript> cells (<Emphasis Type="Italic">P</Emphasis> &gt; 0.05, <Emphasis Type="Italic">n</Emphasis> = 8; Fig. <InternalRef RefID="Fig4">4b</InternalRef>) or GFAP<Superscript>+</Superscript> cells (<Emphasis Type="Italic">P</Emphasis> &gt; 0.05, <Emphasis Type="Italic">n</Emphasis> = 8; Fig. <InternalRef RefID="Fig4">4c</InternalRef>) in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice did not differ from those in the WT mice. Morphological analysis revealed GFAP<Superscript>+</Superscript> stellated-shaped astrocytes with thin processes that denoted a resting phenotype or with thick processes that reflected an activated phenotype [<CitationRef CitationID="CR40">40</CitationRef>]. Notably, the numbers of Iba1<Superscript>+</Superscript> cells (<Emphasis Type="Italic">P</Emphasis> &lt; 0.01, <Emphasis Type="Italic">n</Emphasis> = 8) and GFAP<Superscript>+</Superscript> activated astrocytes (<Emphasis Type="Italic">P</Emphasis> &lt; 0.01, <Emphasis Type="Italic">n</Emphasis> = 8) were significantly increased in the Aβ<Subscript>25–35</Subscript>-KO mice compared with the <Emphasis Type="Italic">seipin</Emphasis>-KO mice, which were reduced by the rosi treatment (Iba1<Superscript>+</Superscript>: <Emphasis Type="Italic">P</Emphasis> &lt; 0.01, <Emphasis Type="Italic">n</Emphasis> = 8; GFAP<Superscript>+</Superscript>: <Emphasis Type="Italic">P</Emphasis> &lt; 0.05, <Emphasis Type="Italic">n</Emphasis> = 8). The inhibitory effects of rosi on the activation of Iba1<Superscript>+</Superscript> cells (<Emphasis Type="Italic">P</Emphasis> &lt; 0.01, <Emphasis Type="Italic">n</Emphasis> = 8) and GFAP<Superscript>+</Superscript> activated astrocytes (<Emphasis Type="Italic">P</Emphasis> &lt; 0.05, <Emphasis Type="Italic">n</Emphasis> = 8) in the Aβ<Subscript>25–35</Subscript>-KO mice could be blocked by the PPARγ antagonist GW9962. By contrast, Aβ<Subscript>25–35</Subscript> mice did not show the changes in the numbers of Iba1<Superscript>+</Superscript> cells (<Emphasis Type="Italic">P</Emphasis> &gt; 0.05, <Emphasis Type="Italic">n</Emphasis> = 8) and GFAP<Superscript>+</Superscript> cells (<Emphasis Type="Italic">P</Emphasis> &gt; 0.05, <Emphasis Type="Italic">n</Emphasis> = 8) compared to the WT mice. Additionally, the Aβ<Subscript>1–42</Subscript> injection could increase the numbers of Iba1<Superscript>+</Superscript> cells (<Emphasis Type="Italic">P</Emphasis> &lt; 0.01, <Emphasis Type="Italic">n</Emphasis> = 8; Additional file <InternalRef RefID="MOESM1">1</InternalRef>: Figure S2) and GFAP<Superscript>+</Superscript> activated astrocytes (<Emphasis Type="Italic">P</Emphasis> &lt; 0.01, <Emphasis Type="Italic">n</Emphasis> = 8) in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice but not in the WT mice, which was sensitive to the rosi treatment (Iba1<Superscript>+</Superscript> cells: <Emphasis Type="Italic">P</Emphasis> &lt; 0.01, <Emphasis Type="Italic">n</Emphasis> = 8; GFAP<Superscript>+</Superscript> cells: <Emphasis Type="Italic">P</Emphasis> &lt; 0.05, <Emphasis Type="Italic">n</Emphasis> = 8).<Figure Category="Standard" Float="Yes" ID="Fig4">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 4</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Activation of PPARγ reduces the enhanced Aβ-induced inflammation by seipin deficiency. <Emphasis Type="Bold">a</Emphasis> The upper panel shows representative fluorescence images by seipin (<Emphasis Type="Italic">red color</Emphasis>, <Emphasis Type="Italic">left column</Emphasis>) and GFAP (<Emphasis Type="Italic">green color</Emphasis>, <Emphasis Type="Italic">middle column</Emphasis>) double immuno-staining in hippocampal CA1 regions of WT mice (<Emphasis Type="Italic">scale bar</Emphasis> = 50 μm). The <Emphasis Type="Italic">white arrows</Emphasis> indicate seipin/GFAP-positive cells (<Emphasis Type="Italic">yellow color</Emphasis>, <Emphasis Type="Italic">right column</Emphasis>). The <Emphasis Type="Italic">bottom panels</Emphasis> shows the representative pictures of seipin (<Emphasis Type="Italic">green color</Emphasis>, <Emphasis Type="Italic">left column</Emphasis>) and Iba1 (<Emphasis Type="Italic">red color</Emphasis>, <Emphasis Type="Italic">middle column</Emphasis>) double immuno-staining in hippocampal CA1 regions of WT mice (<Emphasis Type="Italic">scale bar</Emphasis> = 50 μm). <Emphasis Type="Italic">PcL</Emphasis> pyramidal cell layer, <Emphasis Type="Italic">RL</Emphasis> radiatum layer. <Emphasis Type="Bold">b</Emphasis>, <Emphasis Type="Bold">c</Emphasis> Representative pictures of Iba1<Superscript>+</Superscript> cells (<Emphasis Type="Italic">scale bar</Emphasis> = 50 μm) and GFAP<Superscript>+</Superscript> cells (<Emphasis Type="Italic">scale bar</Emphasis> = 25 μm) in the hippocampal CA1 regions of WT mice (WT), Aβ<Subscript>25–35</Subscript> mice (Aβ), <Emphasis Type="Italic">seipin</Emphasis>-KO mice (KO), Aβ<Subscript>25–35</Subscript>-KO mice (KO/Aβ), and rosi-treated KO/Aβ mice (KO/Aβ/rosi). The <Emphasis Type="Italic">bar graphs</Emphasis> represent the densities of Iba1<Superscript>+</Superscript> microglial and GFAP<Superscript>+</Superscript>-activated astrocytes normalized by the control value obtained from WT mice. <Superscript>**</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. <Emphasis Type="Italic">seipin</Emphasis>-KO mice; <Superscript>#</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.05 and <Superscript>##</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. Aβ<Subscript>25–35</Subscript>-KO mice; <Superscript>+</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.05 and <Superscript>++</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. KO/Aβ/rosi mice (three-way ANOVA with Bonferroni’s test). <Emphasis Type="Bold">d</Emphasis>, <Emphasis Type="Bold">e</Emphasis> Levels of hippocampal TNF-α and IL-1β. *<Emphasis Type="Italic">P</Emphasis> &lt; 0.05 and **<Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. WT mice; <Superscript>#</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.05 and <Superscript>##</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. <Emphasis Type="Italic">seipin</Emphasis>-KO mice; <Superscript>++</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. Aβ<Subscript>25–35</Subscript>-KO mice (three-way ANOVA with Bonferroni’s test)</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO4">
                      <ImageObject Color="Color" FileRef="MediaObjects/12974_2016_598_Fig4_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                        </Para>
                <Para ID="Par28">Further experiment was designed to examine the influence of seipin deficiency on Aβ-induced inflammatory reactions using Western blot. Notably, there were a main effect of genotype for the levels of hippocampal TNF-α (<Emphasis Type="Italic">F</Emphasis>
                           <Subscript>(1, 28)</Subscript> = 29.253, <Emphasis Type="Italic">P</Emphasis> &lt; 0.001; Fig. <InternalRef RefID="Fig4">4d</InternalRef>) and IL-6 (<Emphasis Type="Italic">F</Emphasis>
                           <Subscript>(1, 28)</Subscript> = 65.073, <Emphasis Type="Italic">P</Emphasis> &lt; 0.001; Fig. <InternalRef RefID="Fig4">4e</InternalRef>). Additionally, there was a significant genotype × Aβ<Subscript>25–35</Subscript> interaction, because the levels of TNF-α (<Emphasis Type="Italic">P</Emphasis> &lt; 0.01) and IL-6 (<Emphasis Type="Italic">P</Emphasis> &lt; 0.01) were higher in the Aβ<Subscript>25–35</Subscript>-KO mice than those in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice. However, the levels of TNF-α (<Emphasis Type="Italic">P</Emphasis> &gt; 0.05) and IL-6 (<Emphasis Type="Italic">P</Emphasis> &gt; 0.05) exhibited no differences between the WT mice and Aβ<Subscript>25–35</Subscript> mice. Furthermore, the increased TNF-α and IL-6 levels in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice (TNF-α: <Emphasis Type="Italic">P</Emphasis> &lt; 0.05; IL-6: <Emphasis Type="Italic">P</Emphasis> &lt; 0.01) and the Aβ<Subscript>25–35</Subscript>-KO mice (TNF-α: <Emphasis Type="Italic">P</Emphasis> &lt; 0.01; IL-6: <Emphasis Type="Italic">P</Emphasis> &lt; 0.01) were attenuated by the rosi treatment.</Para>
              </Section2>
              <Section2 ID="Sec15">
                <Heading>Seipin deficiency increases GSK3β activity via PPARγ reduction</Heading>
                <Para ID="Par29">GSK3β has been reported to modulate pro-inflammatory cytokines [<CitationRef CitationID="CR26">26</CitationRef>]. GSK3β activity is negatively and positively regulated by phosphorylation at Ser9 and Tyr216, respectively. To explore the mechanisms underlying the seipin deficiency-increased TNF-α and IL-6, we examined the levels of hippocampal GSK3β phosphorylation (phospho-GSK3β) at Tyr216 and Ser9 [<CitationRef CitationID="CR41">41</CitationRef>]. Compared with the WT mice, the level of Tyr216 phospho-GSK3β was elevated (<Emphasis Type="Italic">P</Emphasis> &lt; 0.01, <Emphasis Type="Italic">n</Emphasis> = 8; Fig. <InternalRef RefID="Fig5">5a</InternalRef>) and the level of Ser9 phospho-GSK3β was reduced in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice (<Emphasis Type="Italic">P</Emphasis> &lt; 0.01, <Emphasis Type="Italic">n</Emphasis> = 8; Fig. <InternalRef RefID="Fig5">5b</InternalRef>); and these levels were not affected by the Aβ<Subscript>25–35</Subscript> injection. Interestingly, the rosi treatment in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice obviously corrected the elevation of Tyr216 phospho-GSK3β (<Emphasis Type="Italic">P</Emphasis> &lt; 0.01, <Emphasis Type="Italic">n</Emphasis> = 8) and the reduction of Ser9 phospho-GSK3β (<Emphasis Type="Italic">P</Emphasis> &lt; 0.01, <Emphasis Type="Italic">n</Emphasis> = 8). Additionally, the rosi treatment of the WT mice increased Ser9 phospho-GSK3β (<Emphasis Type="Italic">P</Emphasis> &lt; 0.01, <Emphasis Type="Italic">n</Emphasis> = 8) but had no effect on Tyr216 phospho-GSK3β (<Emphasis Type="Italic">P</Emphasis> &gt; 0.05, <Emphasis Type="Italic">n</Emphasis> = 8).<Figure Category="Standard" Float="Yes" ID="Fig5">
                    <Caption Language="En">
                      <CaptionNumber>Fig. 5</CaptionNumber>
                      <CaptionContent>
                        <SimplePara>Activation of PPARγ depresses enhanced GSK3β activity by seipin deficiency. <Emphasis Type="Bold">a–c</Emphasis> Levels of hippocampal Tyr216 phospho-GSK3β, Ser9 phospho-GSK3β, and phospho-STAT3 in WT mice (WT), Aβ<Subscript>25–35</Subscript> mice (Aβ), <Emphasis Type="Italic">seipin</Emphasis>-KO mice (KO), Aβ<Subscript>25–35</Subscript>-KO mice (KO/Aβ), and rosi-treated Aβ mice and KO/Aβ mice. Levels of Tyr216 phospho-GSK3β and Ser9 phospho-GSK3β were first normalized to the amount of GSK3β protein and subsequently normalized to the basal values in WT mice. **<Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. WT mice; <Superscript>##</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. Aβ<Subscript>25–35</Subscript>-KO mice (three-way ANOVA). The levels of phospho-STAT3 were normalized to the amount of STAT3 protein and subsequently normalized to the basal values in WT mice. **<Emphasis Type="Italic">P</Emphasis> &lt; 0.01 vs. WT mice; <Superscript>#</Superscript>
                                       <Emphasis Type="Italic">P</Emphasis> &lt; 0.05 vs. Aβ<Subscript>25–35</Subscript>-KO mice (three-way ANOVA with Bonferroni’s test)</SimplePara>
                      </CaptionContent>
                    </Caption>
                    <MediaObject ID="MO5">
                      <ImageObject Color="BlackWhite" FileRef="MediaObjects/12974_2016_598_Fig5_HTML.gif" Format="GIF" Rendition="HTML" Type="LinedrawHalftone"/>
                    </MediaObject>
                  </Figure>
                        </Para>
                <Para ID="Par30">The activation of GSK3β is required to activate tyrosine phosphorylation of STAT3 in astrocytes and microglia [<CitationRef CitationID="CR24">24</CitationRef>]. Similarly, the level of hippocampal STAT phosphorylation (phospho-STAT) in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice was elevated compared with that in the WT mice (<Emphasis Type="Italic">P</Emphasis> &lt; 0.01, <Emphasis Type="Italic">n</Emphasis> = 8; Fig. <InternalRef RefID="Fig5">5c</InternalRef>). The level of phospho-STAT3 in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice was further increased by the rosi treatment (<Emphasis Type="Italic">P</Emphasis> &lt; 0.01, <Emphasis Type="Italic">n</Emphasis> = 8) but was not affected by the Aβ<Subscript>25–35</Subscript> injection (<Emphasis Type="Italic">P</Emphasis> &gt; 0.05, <Emphasis Type="Italic">n</Emphasis> = 8). Additionally, the rosi treatment increased the level of phospho-STAT3 in the WT mice (<Emphasis Type="Italic">P</Emphasis> &lt; 0.05, <Emphasis Type="Italic">n</Emphasis> = 8).</Para>
              </Section2>
            </Section1>
            <Section1 ID="Sec16">
              <Heading>Discussion</Heading>
              <Para ID="Par31">The present study provides, for the first time, in vivo evidence that the seipin deficiency in astrocytes can facilitate the Aβ<Subscript>25–35/1–42</Subscript>-induced neuroinflammation to aggravate the Aβ<Subscript>25–35/1–42</Subscript> neurotoxicity. This conclusion was deduced mainly from the following observations: (1) seipin was highly expressed in hippocampal pyramidal cells and astrocytes; (2) the seipin deficiency did not alter the number of neuronal cells, astrocytes, and microglia, but the levels of IL-6/TNF-α were higher in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice than those in WT mice; (3) the injection (i.c.v.) of Aβ<Subscript>25–35</Subscript> (1.2 nmol/mouse) or Aβ<Subscript>1–42</Subscript> (0.1 nmol/mouse) could stimulate the activation of astrocytes and microglia and further increased the expression of IL-6/TNF-α in <Emphasis Type="Italic">seipin</Emphasis>-KO mice, but not in the WT mice; (4) the injection (i.c.v.) of Aβ<Subscript>25–35</Subscript> or Aβ<Subscript>1–42</Subscript>, at the non-neurotoxic doses in WT mice, caused approximately 30–35 % death of pyramidal cells with a significant increase of apoptotic cells in hippocampal CA1 of the <Emphasis Type="Italic">seipin</Emphasis>-KO mice leading to the impairment of spatial memory.</Para>
              <Section2 ID="Sec17">
                <Heading>Seipin deficiency in astrocytes facilitates Aβ-neuroinflammation via the reduction of PPARγ</Heading>
                <Para ID="Par32">The treatment of astrocytes and microglia with Aβ<Subscript>1–42</Subscript> can increase the production of IL-6 and TNF-α, which is inhibited by the activation of PPARγ [<CitationRef CitationID="CR42">42</CitationRef>]. The PPARγ agonists can prevent the overproduction of IL-6 and TNF-α in astrocytes and microglia treated with lipopolysaccharide (LPS) [<CitationRef CitationID="CR43">43</CitationRef>]. The injection (i.c.v.) of Aβ<Subscript>25–35</Subscript> stimulates microglial activation in the brains of C57BL/6J mice [<CitationRef CitationID="CR44">44</CitationRef>]. The injection (i.c.v.) of Aβ<Subscript>25–35</Subscript> (1.2 nmol/mouse) or Aβ<Subscript>1–42</Subscript> (0.1 nmol/mouse) was insufficient to stimulate the activation of astrocytes and microglia or to increase the production of TNF-α or IL-6 in WT mice. However, this injection (i.c.v.) of Aβ<Subscript>25–35</Subscript> or Aβ<Subscript>1–42</Subscript> in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice caused the activation of astrocytes and microglia with an obvious increase in the level of TNF-α or IL-6. Interestingly, in particular, the activation of PPARγ in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice was able to prevent the Aβ<Subscript>25–35/1–42</Subscript>-induced neuroinflammation. Similarly, PPARγ-deficient heterozygous mice develop an exacerbated experimental allergic encephalomyelitis (EAE) in comparison with the wild-type littermates [<CitationRef CitationID="CR15">15</CitationRef>]. The exacerbation of EAE by the PPARγ antagonists associates with an augmented neural inflammation [<CitationRef CitationID="CR16">16</CitationRef>]. Astrocytes and microglia are fundamental cellular targets for the beneficial effects of PPARγ ligands [<CitationRef CitationID="CR13">13</CitationRef>]. We observed the seipin expression in hippocampal astrocytes. Although the number of astrocytes in the hippocampal CA1 region of the <Emphasis Type="Italic">seipin</Emphasis>-KO mice did not differ in comparison with the WT mice, the levels of hippocampal TNF-α and IL-6 in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice were higher than those in the WT mice. In particular, the elevation of TNF-α or IL-6 in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice was reduced by the PPARγ agonist. Thus, it may be possible that the reduction of PPARγ leads to the overproduction of pro-inflammatory cytokines in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice, which facilitates the Aβ<Subscript>25–35/1–42</Subscript>-induced neuroinflammation. Another indirect but important supporting data is that the increased TNF-α and IL-6 in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice could be corrected by the activation of PPARγ. Therefore, the findings give an indication that the seipin deficiency in astrocytes is able to facilitate the Aβ-induced neuroinflammation probably through reducing PPARγ to elevate the levels of TNF-α and IL-6.</Para>
              </Section2>
              <Section2 ID="Sec18">
                <Heading>Seipin deficiency enhances GSK3β activity to increase pro-inflammatory cytokines</Heading>
                <Para ID="Par33">GSK3β has been identified as a strong promoter of pro-inflammatory cytokines, including IL-6 and TNF-α [<CitationRef CitationID="CR25">25</CitationRef>, <CitationRef CitationID="CR26">26</CitationRef>]. The inhibition of GSK3β increases inflammatory tolerance and reduces inflammatory sensitization in the brain [<CitationRef CitationID="CR45">45</CitationRef>]. GSK3β inhibition in glial cells reduces pro-inflammatory responses by blocking STAT3 signaling [<CitationRef CitationID="CR46">46</CitationRef>]. The inhibition of GSK3 reduces STAT3 activation, IL-6 production, and GFAP up-regulation by LPS-stimulated primary glia [<CitationRef CitationID="CR47">47</CitationRef>]. The activation of PPARγ potentially suppresses the activator of STAT [<CitationRef CitationID="CR48">48</CitationRef>]. The level of STAT3 phosphorylation was significantly increased in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice [<CitationRef CitationID="CR10">10</CitationRef>]. STAT3 activation is highly dependent on GSK3β in mouse primary astrocytes [<CitationRef CitationID="CR24">24</CitationRef>]. Notably, the catalytic activity of GSK3β in <Emphasis Type="Italic">seipin</Emphasis>-KO mice was enhanced as indicated by the elevation of Tyr216 phospho-GSK3β and the reduction of Ser9 phospho-GSK3β. The activation of PPARγ regulates negatively the expressions of GSK3β [<CitationRef CitationID="CR49">49</CitationRef>], but the level of GSK3β protein failed to be increased in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice. Strangely enough, the administration of rosi to the <Emphasis Type="Italic">seipin</Emphasis>-KO mice could suppress the increase of GSK3β activity but further enhanced the phosphorylation of STAT3. Therefore, it is indicated that seipin deficiency in astrocytes through reducing PPARγ enhances the GSK3β activity rather than the STAT3 signaling to increase the production of TNF-α and IL-6. On the other hand, GSK3β regulates interferon-γ (IFN-γ) signaling and is involved in IFN-γ-induced inflammation [<CitationRef CitationID="CR50">50</CitationRef>]. Thus, further studies are required to examine whether the GSK3β activity in <Emphasis Type="Italic">seipin</Emphasis>-KO mice through synergistically facilitating IFN-γ-induced STAT1 activation increases the production of TNF-α [<CitationRef CitationID="CR41">41</CitationRef>].</Para>
              </Section2>
              <Section2 ID="Sec19">
                <Heading>Seipin deficiency enhances Aβ-neurotoxicity via the reduction of PPARγ</Heading>
                <Para ID="Par34">A principal finding in this study is that seipin deficiency in hippocampal neuronal cells enhances the Aβ<Subscript>25–35/1–42</Subscript> neurotoxicity as indicated by a massive death of pyramidal cells in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice treated with the Aβ<Subscript>25–35</Subscript> (1.2 nmol/mouse) or Aβ<Subscript>1–42</Subscript> (0.1 nmol/mouse), generally non-neurotoxic doses in the WT mice or control mice [<CitationRef CitationID="CR29">29</CitationRef>]. The level of the hippocampal PPARγ was significantly reduced in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice. The decline of PPARγ in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice [<CitationRef CitationID="CR11">11</CitationRef>] or the neuronal specific PPARγ knockout in mice [<CitationRef CitationID="CR51">51</CitationRef>] did not cause the loss of neuronal cells in the hippocampus. The rosi treatment could significantly reduce the Aβ<Subscript>25–35/1–42</Subscript>-induced death of pyramidal cells in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice. Activated microglia and reactive astrocytes can produce cytokines, reactive oxygen species, and other neurotoxic substances to cause neuronal apoptosis and other series of pathologic events. The progressive neuroinflammation and neuronal apoptosis in AD is considered to be a consequence of the Aβ-neurotoxic properties [<CitationRef CitationID="CR52">52</CitationRef>, <CitationRef CitationID="CR53">53</CitationRef>]. Our data support the notion that Aβ<Subscript>25–35/1–42</Subscript>-induced neuroinflammation in the <Emphasis Type="Italic">seipin</Emphasis>-KO mice causes the death of neuronal cells. Zhao et al. [<CitationRef CitationID="CR51">51</CitationRef>] reported that neuronal PPARγ deficiency increased susceptibility to brain damage after cerebral ischemia through suppressing the expressions of Cu-Zn superoxide dismutase (SOD1), catalase (CAT), and glutathione S-transferase (GST). However, the levels of hippocampal <Emphasis Type="Italic">SOD1</Emphasis>, <Emphasis Type="Italic">CAT</Emphasis>, and <Emphasis Type="Italic">GST</Emphasis> expression in <Emphasis Type="Italic">seipin</Emphasis>-KO mice did not differ from WT mice (data not shown). Additionally, Ito et al. reported that mutations (N88S/S90L) of the seipin gene can cause the formation of cytoplasmic inclusions and enhance ubiquitination, which leads to endoplasmic reticulum (ER) stress [<CitationRef CitationID="CR54">54</CitationRef>]. However, this idea is not supported because the levels of the ER stress makers BiP and CHOP in <Emphasis Type="Italic">seipin</Emphasis>-KO mice are not increased [<CitationRef CitationID="CR11">11</CitationRef>].</Para>
              </Section2>
            </Section1>
            <Section1 ID="Sec20">
              <Heading>Conclusions</Heading>
              <Para ID="Par35">Using the <Emphasis Type="Italic">seipin</Emphasis>-KO mice with reduction of PPARγ, we observed that seipin deficiency elevated the activity of GSK3β to enhance the production of TNF-α and IL-6, which in turn triggered and strengthened the Aβ<Subscript>25–35</Subscript>-induced inflammatory responses leading to the death of neuronal cells and the spatial cognitive deficits. This is particularly true of neuroinflammation, which contributes to a broad range of neurodegenerative diseases [<CitationRef CitationID="CR55">55</CitationRef>]. Although much more work needs to be performed in the future, this is the first report to demonstrate that the expression of seipin in hippocampal astrocytes is required for regulating the inflammatory responses and preventing the neurodegeneration.</Para>
            </Section1>
            <Section1 ID="Sec21">
              <Heading>Highlights</Heading>
              <Para ID="Par36">
                <OrderedList>
                  <ListItem>
                    <ItemNumber>(1)</ItemNumber>
                    <ItemContent>
                      <Para ID="Par37">Hippocampal GSK3β activity and IL-6/TNF-α were slightly increased in seipin-KO mice.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>(2)</ItemNumber>
                    <ItemContent>
                      <Para ID="Par38">PPARγ agonist inhibits increased GSK3β activity and IL-6/TNF-α in KO mice.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>(3)</ItemNumber>
                    <ItemContent>
                      <Para ID="Par39">Low-dose Aβ<Subscript>25–35</Subscript> causes death of pyramidal cells in KO mice, not in WT mice.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>(4)</ItemNumber>
                    <ItemContent>
                      <Para ID="Par40">Aβ<Subscript>25–35</Subscript> activates microglia and astrocytes to increases IL-6/TNF-α in KO mice.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>(5)</ItemNumber>
                    <ItemContent>
                      <Para ID="Par41">PPARγ agonist prevents Aβ<Subscript>25–35</Subscript>-neuroinflammation and -neurotoxicity in KO mice.</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section1>
            <Section1 ID="Sec22">
              <Heading>Abbreviations</Heading>
              <Para ID="Par42">AD, Alzheimer’s disease; AGPAT2, 1-acylglycerol-3-phosphate-O-acyl transferase 2; Aβ, β-amyloid; BSCL2, Berardinelli-Seip congenital lipodystrophy 2; CGL, congenital generalized lipodystrophy; GFAP, glial fibrillary acidic protein; GSK3, glycogen synthase kinase-3; i.c.v., intracerebroventricular; Iba1<Superscript>+</Superscript>, ionized calcium-binding adaptor molecule 1-positive; IL-6, interleukin-6; PA, phosphatidic acid; PPARγ, peroxisome proliferator-activated receptor gamma; <Emphasis Type="Italic">seipin</Emphasis>-KO mice, seipin knockout mice; STAT, signal transducer and activator of transcription; TNF-α, tumor necrosis factor-α</Para>
            </Section1>
          </Body>
          <BodyRef FileRef="BodyRef/PDF/12974_2016_Article_598.pdf" TargetType="OnlinePDF"/>
          <ArticleBackmatter>
            <Acknowledgments>
              <Heading>Acknowledgments</Heading>
              <SimplePara>This work was supported by the National 973 Basic Research Program of China (grant number 2014CB943303) and the National Natural Science Foundation of China (grant numbers 31171440, 81361120247, and 81471157) to Chen L.</SimplePara>
              <FormalPara ID="FPar1" RenderingStyle="Style1">
                <Heading>Availability of data and materials</Heading>
                <Para ID="Par43">We agree to share our data obtained in the study.</Para>
              </FormalPara>
              <FormalPara ID="FPar2" RenderingStyle="Style1">
                <Heading>Authors’ contributions</Heading>
                <Para ID="Par44">In this study, YQ performed the histological examination of the neurogenesis, Western blot, and RT-PCR analysis. JY participated in the seipin immuno-staining and all statistical analysis. JH, GL, and BZ contributed to the animal care and behavioral examination. GL, QW helped to edit the manuscript. LC carried out the experimental design and finished the manuscript. All authors read and approved the final manuscript.</Para>
              </FormalPara>
              <FormalPara ID="FPar3" RenderingStyle="Style1">
                <Heading>Competing interests</Heading>
                <Para ID="Par45">The authors declare that they have no competing interests.</Para>
              </FormalPara>
              <FormalPara ID="FPar4" RenderingStyle="Style1">
                <Heading>Consent for publication</Heading>
                <Para ID="Par46">Not applicable.</Para>
              </FormalPara>
              <FormalPara ID="FPar5" RenderingStyle="Style1">
                <Heading>Ethics approval and consent to participate</Heading>
                <Para ID="Par47">The use of animals was approved by the Ethic Committee of Nanjing Medical University (2014, No. 153).</Para>
              </FormalPara>
            </Acknowledgments>
            <Appendix ID="App1" OutputMedium="Online">
              <Section1 ID="Sec23">
                <Heading>Additional file</Heading>
                <Para ID="Par48">
                  <MediaObject ID="MOESM1">
                    <DataObject FileRef="MediaObjects/12974_2016_598_MOESM1_ESM.doc">
                      <Caption Language="En">
                        <CaptionNumber>Additional file 1:</CaptionNumber>
                        <CaptionContent>
                          <SimplePara>Effects of neuronal seipin knockout on Aβ<Subscript>1-42</Subscript>-induced neurotoxicity and neuroinflammation. (116 KB)</SimplePara>
                        </CaptionContent>
                      </Caption>
                    </DataObject>
                  </MediaObject>
                </Para>
              </Section1>
            </Appendix>
            <Bibliography ID="Bib1">
              <Heading>References</Heading>
              <Citation ID="CR1">
                <CitationNumber>1.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AK</Initials>
                    <FamilyName>Agarwal</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Garg</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Congenital generalized lipodystrophy: significance of triglyceride biosynthetic pathways</ArticleTitle>
                  <JournalTitle>Trends Endocrinol Metab</JournalTitle>
                  <VolumeID>14</VolumeID>
                  <FirstPage>214</FirstPage>
                  <LastPage>221</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXkvVCmu7w%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S1043-2760(03)00078-X</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>12826327</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Agarwal AK, Garg A. Congenital generalized lipodystrophy: significance of triglyceride biosynthetic pathways. Trends Endocrinol Metab. 2003;14:214–21.</BibUnstructured>
              </Citation>
              <Citation ID="CR2">
                <CitationNumber>2.</CitationNumber>
                <BibUnstructured>Magre J, Delepine M, Khallouf E, Gedde-Dahl Jr T, Van Maldergem L, Sobel E, Papp J, Meier M, Megarbane A, Bachy A, et al. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet. 2001;28:365–70.</BibUnstructured>
              </Citation>
              <Citation ID="CR3">
                <CitationNumber>3.</CitationNumber>
                <BibUnstructured>Van Maldergem L, Magre J, Khallouf TE, Gedde-Dahl Jr T, Delepine M, Trygstad O, Seemanova E, Stephenson T, Albott CS, Bonnici F, et al. Genotype-phenotype relationships in Berardinelli-Seip congenital lipodystrophy. J Med Genet. 2002;39:722–33. doi: <ExternalRef><RefSource>10.1136/jmg.39.10.722</RefSource><RefTarget TargetType="DOI" Address="10.1136/jmg.39.10.722"/></ExternalRef>.</BibUnstructured>
              </Citation>
              <Citation ID="CR4">
                <CitationNumber>4.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Rajab</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Khaburi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Spranger</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Kunze</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Spranger</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Congenital generalized lipodystrophy, mental retardation, deafness, short stature, and slender bones: a newly recognized syndrome?</ArticleTitle>
                  <JournalTitle>Am J Med Genet A</JournalTitle>
                  <VolumeID>121A</VolumeID>
                  <FirstPage>271</FirstPage>
                  <LastPage>276</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD3szosFegug%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/ajmg.a.20245</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>12923870</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Rajab A, Khaburi M, Spranger S, Kunze J, Spranger J. Congenital generalized lipodystrophy, mental retardation, deafness, short stature, and slender bones: a newly recognized syndrome? Am J Med Genet A. 2003;121A:271–6.</BibUnstructured>
              </Citation>
              <Citation ID="CR5">
                <CitationNumber>5.</CitationNumber>
                <BibUnstructured>Ebihara C, Ebihara K, Aizawa-Abe M, Mashimo T, Tomita T, Zhao M, Gumbilai V, Kusakabe T, Yamamoto Y, Aotani D, et al. Seipin is necessary for normal brain development and spermatogenesis in addition to adipogenesis. Hum Mol Genet. 2015;24:4238–49. doi: <ExternalRef><RefSource>10.1093/hmg/ddv156</RefSource><RefTarget TargetType="DOI" Address="10.1093/hmg/ddv156"/></ExternalRef>.</BibUnstructured>
              </Citation>
              <Citation ID="CR6">
                <CitationNumber>6.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AS</Initials>
                    <FamilyName>Garfield</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WS</Initials>
                    <FamilyName>Chan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RJ</Initials>
                    <FamilyName>Dennis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Ito</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LK</Initials>
                    <FamilyName>Heisler</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JJ</Initials>
                    <FamilyName>Rochford</FamilyName>
                  </BibAuthorName>
                  <Year>2012</Year>
                  <ArticleTitle Language="En">Neuroanatomical characterisation of the expression of the lipodystrophy and motor-neuropathy gene Bscl2 in adult mouse brain</ArticleTitle>
                  <JournalTitle>PLoS One</JournalTitle>
                  <VolumeID>7</VolumeID>
                  <FirstPage>e45790</FirstPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC38XhsVGhtb3N</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1371/journal.pone.0045790</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>23049863</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3458087</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Garfield AS, Chan WS, Dennis RJ, Ito D, Heisler LK, Rochford JJ. Neuroanatomical characterisation of the expression of the lipodystrophy and motor-neuropathy gene Bscl2 in adult mouse brain. PLoS One. 2012;7:e45790.</BibUnstructured>
              </Citation>
              <Citation ID="CR7">
                <CitationNumber>7.</CitationNumber>
                <BibUnstructured>Zhou L, Chen T, Li G, Wu C, Wang C, Li L, Sha S, Chen L, Liu G, Chen L. Activation of PPARgamma ameliorates spatial cognitive deficits through restoring expression of AMPA receptors in Seipin knock-out mice. J Neurosci. 2016;36:1242–53.</BibUnstructured>
              </Citation>
              <Citation ID="CR8">
                <CitationNumber>8.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>W</Initials>
                    <FamilyName>Fei</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>X</Initials>
                    <FamilyName>Du</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Yang</FamilyName>
                  </BibAuthorName>
                  <Year>2011</Year>
                  <ArticleTitle Language="En">Seipin, adipogenesis and lipid droplets</ArticleTitle>
                  <JournalTitle>Trends Endocrinol Metab</JournalTitle>
                  <VolumeID>22</VolumeID>
                  <FirstPage>204</FirstPage>
                  <LastPage>210</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3MXnslOgtLo%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.tem.2011.02.004</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>21497513</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Fei W, Du X, Yang H. Seipin, adipogenesis and lipid droplets. Trends Endocrinol Metab. 2011;22:204–10.</BibUnstructured>
              </Citation>
              <Citation ID="CR9">
                <CitationNumber>9.</CitationNumber>
                <BibUnstructured>Prieur X, Dollet L, Takahashi M, Nemani M, Pillot B, Le May C, Mounier C, Takigawa-Imamura H, Zelenika D, Matsuda F, et al. Thiazolidinediones partially reverse the metabolic disturbances observed in Bscl2/seipin-deficient mice. Diabetologia. 2013;56:1813–25. doi: <ExternalRef><RefSource>10.1007/s00125-013-2926-9</RefSource><RefTarget TargetType="DOI" Address="10.1007/s00125-013-2926-9"/></ExternalRef>.</BibUnstructured>
              </Citation>
              <Citation ID="CR10">
                <CitationNumber>10.</CitationNumber>
                <BibUnstructured>Li G, Zhou L, Zhu Y, Wang C, Sha S, Xian X, Ji Y, Liu G, Chen L. Seipin knockout in mice impairs stem cell proliferation and progenitor cell differentiation in the adult hippocampal dentate gyrus via reduced levels of PPARgamma. Dis Model Mech. 2015;8:1615–24.</BibUnstructured>
              </Citation>
              <Citation ID="CR11">
                <CitationNumber>11.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Zhou</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Yin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Liao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Liu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <Year>2014</Year>
                  <ArticleTitle Language="En">Lack of seipin in neurons results in anxiety- and depression-like behaviors via down regulation of PPARgamma</ArticleTitle>
                  <JournalTitle>Hum Mol Genet</JournalTitle>
                  <VolumeID>23</VolumeID>
                  <FirstPage>4094</FirstPage>
                  <LastPage>4102</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC2cXhtFeitbvE</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1093/hmg/ddu126</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>24651066</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Zhou L, Yin J, Wang C, Liao J, Liu G, Chen L. Lack of seipin in neurons results in anxiety- and depression-like behaviors via down regulation of PPARgamma. Hum Mol Genet. 2014;23:4094–102.</BibUnstructured>
              </Citation>
              <Citation ID="CR12">
                <CitationNumber>12.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>GJ</Initials>
                    <FamilyName>Ho</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Drego</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Hakimian</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Masliah</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">Mechanisms of cell signaling and inflammation in Alzheimer’s disease</ArticleTitle>
                  <JournalTitle>Curr Drug Targets Inflamm Allergy</JournalTitle>
                  <VolumeID>4</VolumeID>
                  <FirstPage>247</FirstPage>
                  <LastPage>256</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXlsFelsbY%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.2174/1568010053586237</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>15853747</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Ho GJ, Drego R, Hakimian E, Masliah E. Mechanisms of cell signaling and inflammation in Alzheimer’s disease. Curr Drug Targets Inflamm Allergy. 2005;4:247–56.</BibUnstructured>
              </Citation>
              <Citation ID="CR13">
                <CitationNumber>13.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Landreth</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Q</Initials>
                    <FamilyName>Jiang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Mandrekar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Heneka</FamilyName>
                  </BibAuthorName>
                  <Year>2008</Year>
                  <ArticleTitle Language="En">PPARgamma agonists as therapeutics for the treatment of Alzheimer’s disease</ArticleTitle>
                  <JournalTitle>Neurotherapeutics</JournalTitle>
                  <VolumeID>5</VolumeID>
                  <FirstPage>481</FirstPage>
                  <LastPage>489</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1cXhtVOgtLrL</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.nurt.2008.05.003</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>18625459</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2593876</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Landreth G, Jiang Q, Mandrekar S, Heneka M. PPARgamma agonists as therapeutics for the treatment of Alzheimer’s disease. Neurotherapeutics. 2008;5:481–9.</BibUnstructured>
              </Citation>
              <Citation ID="CR14">
                <CitationNumber>14.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>MT</Initials>
                    <FamilyName>Heneka</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>V</Initials>
                    <FamilyName>Gavrilyuk</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GE</Initials>
                    <FamilyName>Landreth</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MK</Initials>
                    <FamilyName>O’Banion</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Weinberg</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DL</Initials>
                    <FamilyName>Feinstein</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Noradrenergic depletion increases inflammatory responses in brain: effects on IkappaB and HSP70 expression</ArticleTitle>
                  <JournalTitle>J Neurochem</JournalTitle>
                  <VolumeID>85</VolumeID>
                  <FirstPage>387</FirstPage>
                  <LastPage>398</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXjtlylsrg%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1046/j.1471-4159.2003.01694.x</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>12675915</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Heneka MT, Gavrilyuk V, Landreth GE, O’Banion MK, Weinberg G, Feinstein DL. Noradrenergic depletion increases inflammatory responses in brain: effects on IkappaB and HSP70 expression. J Neurochem. 2003;85:387–98.</BibUnstructured>
              </Citation>
              <Citation ID="CR15">
                <CitationNumber>15.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Natarajan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Muthian</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Barak</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RM</Initials>
                    <FamilyName>Evans</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JJ</Initials>
                    <FamilyName>Bright</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Peroxisome proliferator-activated receptor-gamma-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis</ArticleTitle>
                  <JournalTitle>J Immunol</JournalTitle>
                  <VolumeID>171</VolumeID>
                  <FirstPage>5743</FirstPage>
                  <LastPage>5750</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.4049/jimmunol.171.11.5743</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>14634082</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Natarajan C, Muthian G, Barak Y, Evans RM, Bright JJ. Peroxisome proliferator-activated receptor-gamma-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis. J Immunol. 2003;171:5743–50.</BibUnstructured>
              </Citation>
              <Citation ID="CR16">
                <CitationNumber>16.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>HP</Initials>
                    <FamilyName>Raikwar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Muthian</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Rajasingh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Johnson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JJ</Initials>
                    <FamilyName>Bright</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">PPARgamma antagonists exacerbate neural antigen-specific Th1 response and experimental allergic encephalomyelitis</ArticleTitle>
                  <JournalTitle>J Neuroimmunol</JournalTitle>
                  <VolumeID>167</VolumeID>
                  <FirstPage>99</FirstPage>
                  <LastPage>107</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXpvFartrk%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.jneuroim.2005.06.026</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>16091293</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Raikwar HP, Muthian G, Rajasingh J, Johnson C, Bright JJ. PPARgamma antagonists exacerbate neural antigen-specific Th1 response and experimental allergic encephalomyelitis. J Neuroimmunol. 2005;167:99–107.</BibUnstructured>
              </Citation>
              <Citation ID="CR17">
                <CitationNumber>17.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>WY</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MS</Initials>
                    <FamilyName>Tan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JT</Initials>
                    <FamilyName>Yu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Tan</FamilyName>
                  </BibAuthorName>
                  <Year>2015</Year>
                  <ArticleTitle Language="En">Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease</ArticleTitle>
                  <JournalTitle>Ann Transl Med</JournalTitle>
                  <VolumeID>3</VolumeID>
                  <FirstPage>136</FirstPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC2MXhsFKjurfP</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>26207229</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>4486922</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Wang WY, Tan MS, Yu JT, Tan L. Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease. Ann Transl Med. 2015;3:136.</BibUnstructured>
              </Citation>
              <Citation ID="CR18">
                <CitationNumber>18.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JB</Initials>
                    <FamilyName>Jahrling</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CM</Initials>
                    <FamilyName>Hernandez</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Denner</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KT</Initials>
                    <FamilyName>Dineley</FamilyName>
                  </BibAuthorName>
                  <Year>2014</Year>
                  <ArticleTitle Language="En">PPARgamma recruitment to active ERK during memory consolidation is required for Alzheimer’s disease-related cognitive enhancement</ArticleTitle>
                  <JournalTitle>J Neurosci</JournalTitle>
                  <VolumeID>34</VolumeID>
                  <FirstPage>4054</FirstPage>
                  <LastPage>4063</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1523/JNEUROSCI.4024-13.2014</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>24623782</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>3951699</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Jahrling JB, Hernandez CM, Denner L, Dineley KT. PPARgamma recruitment to active ERK during memory consolidation is required for Alzheimer’s disease-related cognitive enhancement. J Neurosci. 2014;34:4054–63.</BibUnstructured>
              </Citation>
              <Citation ID="CR19">
                <CitationNumber>19.</CitationNumber>
                <BibUnstructured>Denner LA, Rodriguez-Rivera J, Haidacher SJ, Jahrling JB, Carmical JR, Hernandez CM, Zhao Y, Sadygov RG, Starkey JM, Spratt H, et al. Cognitive enhancement with rosiglitazone links the hippocampal PPARgamma and ERK MAPK signaling pathways. J Neurosci. 2012;32:16725–16735a.</BibUnstructured>
              </Citation>
              <Citation ID="CR20">
                <CitationNumber>20.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Kapadia</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JH</Initials>
                    <FamilyName>Yi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Vemuganti</FamilyName>
                  </BibAuthorName>
                  <Year>2008</Year>
                  <ArticleTitle Language="En">Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists</ArticleTitle>
                  <JournalTitle>Front Biosci</JournalTitle>
                  <VolumeID>13</VolumeID>
                  <FirstPage>1813</FirstPage>
                  <LastPage>1826</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1cXhs1Cgtr8%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.2741/2802</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>17981670</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2734868</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kapadia R, Yi JH, Vemuganti R. Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists. Front Biosci. 2008;13:1813–26.</BibUnstructured>
              </Citation>
              <Citation ID="CR21">
                <CitationNumber>21.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Gasparini</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Ongini</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Wenk</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer’s disease: old and new mechanisms of action</ArticleTitle>
                  <JournalTitle>J Neurochem</JournalTitle>
                  <VolumeID>91</VolumeID>
                  <FirstPage>521</FirstPage>
                  <LastPage>536</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXpsFelsLo%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/j.1471-4159.2004.02743.x</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>15485484</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Gasparini L, Ongini E, Wenk G. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer’s disease: old and new mechanisms of action. J Neurochem. 2004;91:521–36.</BibUnstructured>
              </Citation>
              <Citation ID="CR22">
                <CitationNumber>22.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>EJ</Initials>
                    <FamilyName>Park</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SY</Initials>
                    <FamilyName>Park</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>EH</Initials>
                    <FamilyName>Joe</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Jou</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia</ArticleTitle>
                  <JournalTitle>J Biol Chem</JournalTitle>
                  <VolumeID>278</VolumeID>
                  <FirstPage>14747</FirstPage>
                  <LastPage>14752</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXjtVCmtb4%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1074/jbc.M210819200</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>12584205</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Park EJ, Park SY, Joe EH, Jou I. 15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia. J Biol Chem. 2003;278:14747–52.</BibUnstructured>
              </Citation>
              <Citation ID="CR23">
                <CitationNumber>23.</CitationNumber>
                <BibUnstructured>He F, Ge W, Martinowich K, Becker-Catania S, Coskun V, Zhu W, Wu H, Castro D, Guillemot F, Fan G, et al. A positive autoregulatory loop of Jak-STAT signaling controls the onset of astrogliogenesis. Nat Neurosci. 2005;8:616–25. doi: <ExternalRef><RefSource>10.1038/nn1440</RefSource><RefTarget TargetType="DOI" Address="10.1038/nn1440"/></ExternalRef>.</BibUnstructured>
              </Citation>
              <Citation ID="CR24">
                <CitationNumber>24.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Beurel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RS</Initials>
                    <FamilyName>Jope</FamilyName>
                  </BibAuthorName>
                  <Year>2008</Year>
                  <ArticleTitle Language="En">Differential regulation of STAT family members by glycogen synthase kinase-3</ArticleTitle>
                  <JournalTitle>J Biol Chem</JournalTitle>
                  <VolumeID>283</VolumeID>
                  <FirstPage>21934</FirstPage>
                  <LastPage>21944</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1cXpt1arsLk%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1074/jbc.M802481200</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>18550525</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2494932</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Beurel E, Jope RS. Differential regulation of STAT family members by glycogen synthase kinase-3. J Biol Chem. 2008;283:21934–44.</BibUnstructured>
              </Citation>
              <Citation ID="CR25">
                <CitationNumber>25.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>RS</Initials>
                    <FamilyName>Jope</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CJ</Initials>
                    <FamilyName>Yuskaitis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Beurel</FamilyName>
                  </BibAuthorName>
                  <Year>2007</Year>
                  <ArticleTitle Language="En">Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics</ArticleTitle>
                  <JournalTitle>Neurochem Res</JournalTitle>
                  <VolumeID>32</VolumeID>
                  <FirstPage>577</FirstPage>
                  <LastPage>595</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2sXjtlynu7w%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s11064-006-9128-5</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>16944320</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Jope RS, Yuskaitis CJ, Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res. 2007;32:577–95.</BibUnstructured>
              </Citation>
              <Citation ID="CR26">
                <CitationNumber>26.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Martin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Rehani</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RS</Initials>
                    <FamilyName>Jope</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SM</Initials>
                    <FamilyName>Michalek</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3</ArticleTitle>
                  <JournalTitle>Nat Immunol</JournalTitle>
                  <VolumeID>6</VolumeID>
                  <FirstPage>777</FirstPage>
                  <LastPage>784</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXmtlSisL0%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/ni1221</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>16007092</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>1933525</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Martin M, Rehani K, Jope RS, Michalek SM. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol. 2005;6:777–84.</BibUnstructured>
              </Citation>
              <Citation ID="CR27">
                <CitationNumber>27.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Kubo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Nishimura</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Oda</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Amyloid beta-peptide alters the distribution of early endosomes and inhibits phosphorylation of Akt in the presence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)</ArticleTitle>
                  <JournalTitle>Brain Res Mol Brain Res</JournalTitle>
                  <VolumeID>106</VolumeID>
                  <FirstPage>94</FirstPage>
                  <LastPage>100</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XnvVOltrg%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0169-328X(02)00416-3</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>12393269</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kubo T, Nishimura S, Oda T. Amyloid beta-peptide alters the distribution of early endosomes and inhibits phosphorylation of Akt in the presence of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). Brain Res Mol Brain Res. 2002;106:94–100.</BibUnstructured>
              </Citation>
              <Citation ID="CR28">
                <CitationNumber>28.</CitationNumber>
                <BibUnstructured>Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, Yates J, Cotman C, Glabe C. Assembly and aggregation properties of synthetic Alzheimer’s A4/beta amyloid peptide analogs. J Biol Chem. 1992;267:546–54.</BibUnstructured>
              </Citation>
              <Citation ID="CR29">
                <CitationNumber>29.</CitationNumber>
                <BibUnstructured>Chen L, Wang H, Zhang Z, Li Z, He D, Sokabe M, Chen L. DMXB (GTS-21) ameliorates the cognitive deficits in beta amyloid(25-35(-)) injected mice through preventing the dysfunction of alpha7 nicotinic receptor. J Neurosci Res. 2010;88:1784–94.</BibUnstructured>
              </Citation>
              <Citation ID="CR30">
                <CitationNumber>30.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Maurice</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>BP</Initials>
                    <FamilyName>Lockhart</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Privat</FamilyName>
                  </BibAuthorName>
                  <Year>1996</Year>
                  <ArticleTitle Language="En">Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction</ArticleTitle>
                  <JournalTitle>Brain Res</JournalTitle>
                  <VolumeID>706</VolumeID>
                  <FirstPage>181</FirstPage>
                  <LastPage>193</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK28Xns1yitQ%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0006-8993(95)01032-7</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>8822355</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Maurice T, Lockhart BP, Privat A. Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction. Brain Res. 1996;706:181–93.</BibUnstructured>
              </Citation>
              <Citation ID="CR31">
                <CitationNumber>31.</CitationNumber>
                <BibUnstructured>Bouter Y, Dietrich K, Wittnam JL, Rezaei-Ghaleh N, Pillot T, Papot-Couturier S, Lefebvre T, Sprenger F, Wirths O, Zweckstetter M, Bayer TA. N-truncated amyloid beta (Abeta) 4-42 forms stable aggregates and induces acute and long-lasting behavioral deficits. Acta Neuropathol. 2013;126:189–205.</BibUnstructured>
              </Citation>
              <Citation ID="CR32">
                <CitationNumber>32.</CitationNumber>
                <BibUnstructured>Jin H, Chen T, Li G, Wang C, Zhang B, Cao X, Sha S, Wan Q, Chen L. Dose-dependent neuroprotection and neurotoxicity of simvastatin through reduction of farnesyl pyrophosphate in mice treated with intracerebroventricular injection of Abeta 1-42. J Alzheimers Dis. 2016;50:501–16.</BibUnstructured>
              </Citation>
              <Citation ID="CR33">
                <CitationNumber>33.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Sheroziya</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Timofeev</FamilyName>
                  </BibAuthorName>
                  <Year>2014</Year>
                  <ArticleTitle Language="En">Global intracellular slow-wave dynamics of the thalamocortical system</ArticleTitle>
                  <JournalTitle>J Neurosci</JournalTitle>
                  <VolumeID>34</VolumeID>
                  <FirstPage>8875</FirstPage>
                  <LastPage>8893</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC2cXhvV2ltbjJ</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1523/JNEUROSCI.4460-13.2014</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>24966387</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>4069359</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sheroziya M, Timofeev I. Global intracellular slow-wave dynamics of the thalamocortical system. J Neurosci. 2014;34:8875–93.</BibUnstructured>
              </Citation>
              <Citation ID="CR34">
                <CitationNumber>34.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Li</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Zhou</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Sha</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <Year>2015</Year>
                  <ArticleTitle Language="En">Simvastatin prevents beta-amyloid25-35-impaired neurogenesis in hippocampal dentate gyrus through alpha7nAChR-dependent cascading PI3K-Akt and increasing BDNF via reduction of farnesyl pyrophosphate</ArticleTitle>
                  <JournalTitle>Neuropharmacology</JournalTitle>
                  <VolumeID>97</VolumeID>
                  <FirstPage>122</FirstPage>
                  <LastPage>132</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC2MXhtVWgurfE</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.neuropharm.2015.05.020</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>26051402</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Wang C, Chen T, Li G, Zhou L, Sha S, Chen L. Simvastatin prevents beta-amyloid25-35-impaired neurogenesis in hippocampal dentate gyrus through alpha7nAChR-dependent cascading PI3K-Akt and increasing BDNF via reduction of farnesyl pyrophosphate. Neuropharmacology. 2015;97:122–32.</BibUnstructured>
              </Citation>
              <Citation ID="CR35">
                <CitationNumber>35.</CitationNumber>
                <BibUnstructured>Xia Y, Xia YF, Lv Q, Yue MF, Qiao SM, Yang Y, Wei ZF, Dai Y. Madecassoside ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting the generation of hepatocyte growth factor via PPAR-gamma in colon. Br J Pharmacol. 2016;173:1219–35.</BibUnstructured>
              </Citation>
              <Citation ID="CR36">
                <CitationNumber>36.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>MJ</Initials>
                    <FamilyName>West</FamilyName>
                  </BibAuthorName>
                  <Year>1993</Year>
                  <ArticleTitle Language="En">New stereological methods for counting neurons</ArticleTitle>
                  <JournalTitle>Neurobiol Aging</JournalTitle>
                  <VolumeID>14</VolumeID>
                  <FirstPage>275</FirstPage>
                  <LastPage>285</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DyaK3szns1WmsQ%3D%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0197-4580(93)90112-O</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>8367009</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>West MJ. New stereological methods for counting neurons. Neurobiol Aging. 1993;14:275–85.</BibUnstructured>
              </Citation>
              <Citation ID="CR37">
                <CitationNumber>37.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Karacay</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Mahoney</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Plume</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DJ</Initials>
                    <FamilyName>Bonthius</FamilyName>
                  </BibAuthorName>
                  <Year>2015</Year>
                  <ArticleTitle Language="En">Genetic absence of nNOS worsens fetal alcohol effects in mice. II: microencephaly and neuronal losses</ArticleTitle>
                  <JournalTitle>Alcohol Clin Exp Res</JournalTitle>
                  <VolumeID>39</VolumeID>
                  <FirstPage>221</FirstPage>
                  <LastPage>231</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC2MXivVaqu7k%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1111/acer.12615</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>25664654</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>4331271</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Karacay B, Mahoney J, Plume J, Bonthius DJ. Genetic absence of nNOS worsens fetal alcohol effects in mice. II: microencephaly and neuronal losses. Alcohol Clin Exp Res. 2015;39:221–31.</BibUnstructured>
              </Citation>
              <Citation ID="CR38">
                <CitationNumber>38.</CitationNumber>
                <BibUnstructured>Long JM, Kalehua AN, Muth NJ, Calhoun ME, Jucker M, Hengemihle JM, Ingram DK, Mouton PR. Stereological analysis of astrocyte and microglia in aging mouse hippocampus. Neurobiol Aging. 1998;19:497–503. doi: <ExternalRef><RefSource>10.1016/S0197-4580(98)00088-8</RefSource><RefTarget TargetType="DOI" Address="10.1016/S0197-4580(98)00088-8"/></ExternalRef>.</BibUnstructured>
              </Citation>
              <Citation ID="CR39">
                <CitationNumber>39.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>YJ</Initials>
                    <FamilyName>Yang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Zhang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JH</Initials>
                    <FamilyName>Ding</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Zhou</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Hu</FamilyName>
                  </BibAuthorName>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">Iptakalim protects against MPP+-induced degeneration of dopaminergic neurons in association with astrocyte activation</ArticleTitle>
                  <JournalTitle>Int J Neuropsychopharmacol</JournalTitle>
                  <VolumeID>12</VolumeID>
                  <FirstPage>317</FirstPage>
                  <LastPage>327</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1MXivFert7o%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1017/S1461145708009243</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>18700057</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Yang YJ, Zhang S, Ding JH, Zhou F, Hu G. Iptakalim protects against MPP+-induced degeneration of dopaminergic neurons in association with astrocyte activation. Int J Neuropsychopharmacol. 2009;12:317–27.</BibUnstructured>
              </Citation>
              <Citation ID="CR40">
                <CitationNumber>40.</CitationNumber>
                <BibUnstructured>Dutuit M, Didier-Bazes M, Vergnes M, Mutin M, Conjard A, Akaoka H, Belin MF, Touret M. Specific alteration in the expression of glial fibrillary acidic protein, glutamate dehydrogenase, and glutamine synthetase in rats with genetic absence epilepsy. Glia. 2000;32:15–24. doi: <ExternalRef><RefSource>10.1002/1098-1136(200010)32:1%3C15::AID-GLIA20%3E3.0.CO;2-%23</RefSource><RefTarget TargetType="DOI" Address="10.1002/1098-1136(200010)32:1%3C15::AID-GLIA20%3E3.0.CO;2-%23"/></ExternalRef>.</BibUnstructured>
              </Citation>
              <Citation ID="CR41">
                <CitationNumber>41.</CitationNumber>
                <BibUnstructured>Tsai CC, Kai JI, Huang WC, Wang CY, Wang Y, Chen CL, Fang YT, Lin YS, Anderson R, Chen SH, et al. Glycogen synthase kinase-3beta facilitates IFN-gamma-induced STAT1 activation by regulating Src homology-2 domain-containing phosphatase 2. J Immunol. 2009;183:856–64.</BibUnstructured>
              </Citation>
              <Citation ID="CR42">
                <CitationNumber>42.</CitationNumber>
                <BibUnstructured>Esposito G, Scuderi C, Valenza M, Togna GI, Latina V, De Filippis D, Cipriano M, Carratu MR, Iuvone T, Steardo L. Cannabidiol reduces Abeta-induced neuroinflammation and promotes hippocampal neurogenesis through PPARgamma involvement. PLoS One. 2011;6:e28668.</BibUnstructured>
              </Citation>
              <Citation ID="CR43">
                <CitationNumber>43.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>GE</Initials>
                    <FamilyName>Landreth</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MT</Initials>
                    <FamilyName>Heneka</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer’s disease</ArticleTitle>
                  <JournalTitle>Neurobiol Aging</JournalTitle>
                  <VolumeID>22</VolumeID>
                  <FirstPage>937</FirstPage>
                  <LastPage>944</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXptFylu7k%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0197-4580(01)00296-2</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>11755002</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Landreth GE, Heneka MT. Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer’s disease. Neurobiol Aging. 2001;22:937–44.</BibUnstructured>
              </Citation>
              <Citation ID="CR44">
                <CitationNumber>44.</CitationNumber>
                <BibUnstructured>Park SH, Kim JH, Choi KH, Jang YJ, Bae SS, Choi BT, Shin HK. Hypercholesterolemia accelerates amyloid beta-induced cognitive deficits. Int J Mol Med. 2013;31:577–82.</BibUnstructured>
              </Citation>
              <Citation ID="CR45">
                <CitationNumber>45.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Beurel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RS</Initials>
                    <FamilyName>Jope</FamilyName>
                  </BibAuthorName>
                  <Year>2010</Year>
                  <ArticleTitle Language="En">Glycogen synthase kinase-3 regulates inflammatory tolerance in astrocytes</ArticleTitle>
                  <JournalTitle>Neuroscience</JournalTitle>
                  <VolumeID>169</VolumeID>
                  <FirstPage>1063</FirstPage>
                  <LastPage>1070</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BC3cXps1Wktrc%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.neuroscience.2010.05.044</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>20553816</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2914115</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Beurel E, Jope RS. Glycogen synthase kinase-3 regulates inflammatory tolerance in astrocytes. Neuroscience. 2010;169:1063–70.</BibUnstructured>
              </Citation>
              <Citation ID="CR46">
                <CitationNumber>46.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>D’Angelo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CJ</Initials>
                    <FamilyName>Ek</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Sun</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Zhu</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Sandberg</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Mallard</FamilyName>
                  </BibAuthorName>
                  <Year>2016</Year>
                  <ArticleTitle Language="En">GSK3beta inhibition protects the immature brain from hypoxic-ischaemic insult via reduced STAT3 signalling</ArticleTitle>
                  <JournalTitle>Neuropharmacology</JournalTitle>
                  <VolumeID>101</VolumeID>
                  <FirstPage>13</FirstPage>
                  <LastPage>23</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.neuropharm.2015.09.017</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>26384655</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>D’Angelo B, Ek CJ, Sun Y, Zhu C, Sandberg M, Mallard C. GSK3beta inhibition protects the immature brain from hypoxic-ischaemic insult via reduced STAT3 signalling. Neuropharmacology. 2016;101:13–23.</BibUnstructured>
              </Citation>
              <Citation ID="CR47">
                <CitationNumber>47.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Beurel</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RS</Initials>
                    <FamilyName>Jope</FamilyName>
                  </BibAuthorName>
                  <Year>2009</Year>
                  <ArticleTitle Language="En">Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain</ArticleTitle>
                  <JournalTitle>J Neuroinflammation</JournalTitle>
                  <VolumeID>6</VolumeID>
                  <FirstPage>9</FirstPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1186/1742-2094-6-9</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>19284588</Handle>
                  </Occurrence>
                  <Occurrence Type="PMCID">
                    <Handle>2660311</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Beurel E, Jope RS. Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain. J Neuroinflammation. 2009;6:9.</BibUnstructured>
              </Citation>
              <Citation ID="CR48">
                <CitationNumber>48.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>DC</Initials>
                    <FamilyName>Jones</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>X</Initials>
                    <FamilyName>Ding</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RA</Initials>
                    <FamilyName>Daynes</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent</ArticleTitle>
                  <JournalTitle>J Biol Chem</JournalTitle>
                  <VolumeID>277</VolumeID>
                  <FirstPage>6838</FirstPage>
                  <LastPage>6845</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XitV2mt7o%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1074/jbc.M106908200</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>11726654</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Jones DC, Ding X, Daynes RA. Nuclear receptor peroxisome proliferator-activated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent. J Biol Chem. 2002;277:6838–45.</BibUnstructured>
              </Citation>
              <Citation ID="CR49">
                <CitationNumber>49.</CitationNumber>
                <BibUnstructured>Liu JJ, Dai XJ, Xu Y, Liu PQ, Zhang Y, Liu XD, Fang ZG, Lin DJ, Xiao RZ, Huang RW, Huang HQ. Inhibition of lymphoma cell proliferation by peroxisomal proliferator-activated receptor-gamma ligands via Wnt signaling pathway. Cell Biochem Biophys. 2012;62:19–27.</BibUnstructured>
              </Citation>
              <Citation ID="CR50">
                <CitationNumber>50.</CitationNumber>
                <BibUnstructured>Lin CF, Tsai CC, Huang WC, Wang CY, Tseng HC, Wang Y, Kai JI, Wang SW, Cheng YL. IFN-gamma synergizes with LPS to induce nitric oxide biosynthesis through glycogen synthase kinase-3-inhibited IL-10. J Cell Biochem. 2008;105:746–55.</BibUnstructured>
              </Citation>
              <Citation ID="CR51">
                <CitationNumber>51.</CitationNumber>
                <BibUnstructured>Zhao X, Strong R, Zhang J, Sun G, Tsien JZ, Cui Z, Grotta JC, Aronowski J. Neuronal PPARgamma deficiency increases susceptibility to brain damage after cerebral ischemia. J Neurosci. 2009;29:6186–95.</BibUnstructured>
              </Citation>
              <Citation ID="CR52">
                <CitationNumber>52.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>PS</Initials>
                    <FamilyName>Aisen</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">The potential of anti-inflammatory drugs for the treatment of Alzheimer’s disease</ArticleTitle>
                  <JournalTitle>Lancet Neurol</JournalTitle>
                  <VolumeID>1</VolumeID>
                  <FirstPage>279</FirstPage>
                  <LastPage>284</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXkvFOgsLg%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S1474-4422(02)00133-3</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>12849425</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Aisen PS. The potential of anti-inflammatory drugs for the treatment of Alzheimer’s disease. Lancet Neurol. 2002;1:279–84.</BibUnstructured>
              </Citation>
              <Citation ID="CR53">
                <CitationNumber>53.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>DM</Initials>
                    <FamilyName>Walsh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DJ</Initials>
                    <FamilyName>Selkoe</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Deciphering the molecular basis of memory failure in Alzheimer’s disease</ArticleTitle>
                  <JournalTitle>Neuron</JournalTitle>
                  <VolumeID>44</VolumeID>
                  <FirstPage>181</FirstPage>
                  <LastPage>193</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXovVOks78%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.neuron.2004.09.010</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>15450169</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer’s disease. Neuron. 2004;44:181–93.</BibUnstructured>
              </Citation>
              <Citation ID="CR54">
                <CitationNumber>54.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Ito</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Fujisawa</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Iida</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Suzuki</FamilyName>
                  </BibAuthorName>
                  <Year>2008</Year>
                  <ArticleTitle Language="En">Characterization of seipin/BSCL2, a protein associated with spastic paraplegia 17</ArticleTitle>
                  <JournalTitle>Neurobiol Dis</JournalTitle>
                  <VolumeID>31</VolumeID>
                  <FirstPage>266</FirstPage>
                  <LastPage>277</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD1cXoslOht74%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.nbd.2008.05.004</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>18585921</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Ito D, Fujisawa T, Iida H, Suzuki N. Characterization of seipin/BSCL2, a protein associated with spastic paraplegia 17. Neurobiol Dis. 2008;31:266–77.</BibUnstructured>
              </Citation>
              <Citation ID="CR55">
                <CitationNumber>55.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>NJ</Initials>
                    <FamilyName>Maragakis</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JD</Initials>
                    <FamilyName>Rothstein</FamilyName>
                  </BibAuthorName>
                  <Year>2006</Year>
                  <ArticleTitle Language="En">Mechanisms of disease: astrocytes in neurodegenerative disease</ArticleTitle>
                  <JournalTitle>Nat Clin Pract Neurol</JournalTitle>
                  <VolumeID>2</VolumeID>
                  <FirstPage>679</FirstPage>
                  <LastPage>689</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD28XhtlajurzP</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/ncpneuro0355</Handle>
                  </Occurrence>
                  <Occurrence Type="PID">
                    <Handle>17117171</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Maragakis NJ, Rothstein JD. Mechanisms of disease: astrocytes in neurodegenerative disease. Nat Clin Pract Neurol. 2006;2:679–89.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ArticleBackmatter>
        </Article>
      </Issue>
    </Volume>
  </Journal>
</Publisher>
